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Effect of indomethacin on renal hemodynamics in neonates. B.M Chot,
A.Y. Lim, KH. Yoo, YS. Hong, and J. W. Lee, Department of Pediatrics,
Korea University College of Medicine, Seoul, Korea. Objective: Indometha-
cm, a prostaglandin synthetase inhibitor, is widely used for the constriction
or closure of the patent ductus arteriosus in neonates. Following indo-
methacin therapy, a majority of the infants develop transient renal
dysfunction, as manifested by decreases in urine output, GFR and FENa,
and electrolyte unbalance, as manifested by hyponatremia and hyperka-
lemia. We studied the effect of indomethacin on renal hemodynamics in
neonates with patent ductus arteriosus. Methods: Thirteen neonates with
symptomatic patent ductus arteriosus, who were admitted in NICU at
Korea University Guro Hospital, were treated with a single dose of
indomethacin 0.2 mg/kg i.v. Serum BUN, creatinine, electrolytes and
osmolarity were measured just before and at 12 hours, 24 hours, 3 days
and 5 days after indomethacin administration. Urine collections were
obtained for amount, creatinine, electrolytes and osmolality analyses in
three aliquots, 24 hours before and 0 to 12 and 12 to 24 hours after. We
performed serial measurements of blood flow velocity in the left renal
arteiy, using Color Doppler imaging, in 6 neonates just before and at 10,
30, 45, 60, 75 and 90 minutes after indomethacin administration. Results:
(1) There was a statistically significant increase in serum creatinine only at
12 hours after indomethacin administration, significant decrease in serum
sodium and serum osmolality for a period of at least 3 days after. Urine
output continued to be lower at 0 to 24 hours after indomethacin
administration. Significantly lower creatinine clearances were seen at 0 to
12 hours and lower fractional excretions of filtered sodium were seen at 12
to 24 hours after indomethacin administration. (2) Indomethacin admin-
istration led to a sharp decrease in renal artery blood flow and flow
velocity integral. This effect was maximal at 10 minutes after indomethacin
administration and showed a slow recovery reaching baseline values again.
There was a significant decrease in end-diastolic flow velocity and an
increase in Pourcelot's index for a period of at least 75 minutes after
indomethacin administration. Conclusion: These results suggest that the
indomethacin induced decrease in renal perfusion is one of the etiologic
factors that indomethacin can effect on renal function in neonates.
Clinical study on hemolytic uremic syndrome: Review of 12 cases. J. W.
Kim, M.J. Kwon, J.S. Lee, P.K KIm, H.Y. Lee, and D.S. Han, Dept. of
Pediatrics and Internal Medicine, Yonsei University College of Medicine,
Seoul, Korea. Hemolytic uremic syndrome is characterized by hemolytic
anemia, thrombocytopenia and acute renal failure with the prodrome of
acute gastroenteritis or upper respiratory infection. It usually occurs in
children less than 4 years of age, and is known as the major cause of acute
renal failure in children since the first report by Gasser et al in 1955. The
precise pathogenic mechanism is unknown but infective agents such as
bacteria or viruses are known to be involved and some drugs and a genetic
tendency are also concerned as etiologic factors. The mortality was high in
the past (up to 100%) but recently has fallen below 10%. When multiple
organ systems are involved, mortality is as high as about 70%. The major
prognostic factors are age of onset, presence of diarrheal prodrome,
duration of oliguria or anuria, and number of organ systems involved. Few
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reports are available on etiology, clinical manifestation, progression and
the outcome of disease in Korea. Thus, we investigated the patients who
had visited our hospital and were diagnosed as hemolytic uremic syn-
drome for last 20 years. The male to female ratio was 3:1 and 8 of these
patients were children. The etiologic diseases were acute gastroenteritis in
8 patients, upper respiratory infection in 1 patient, and drug related in 3
patients. Seven out of 8 children patients had the prodrome of diarrhea
and 3 of the 4 were drug induced in adult age. The laboratory findings on
admission were hemoglobin level 6.8 1.9 g/dl, platelet count 87,000
101.113/id, reticulocyte count 4.3 4.7%, BUN 59 31.1 mg/dl,
creatinine 3.7 1.9 mgldl, and GFR was decreased to 31.2 13.8
ml/min/1.73 m2. There is no statistical significance between the children
and the adults in terms of clinical and laboratory findings. The treatments
were peritoneal dialysis in 7 children, plasmapheresis in 1 adult, hemodi-
alysis and plasmapheresis in 2 adults. The mean level of 24 hour urine
protein was 1.347 mg/m2/day in expired cases but with 849 mg/m2/day in
recovered cases. Four patients died, the mortality rate being 33%: 2 in the
children and 2 in the adult. Among the dead, 1 patient died from a central
nervous system complication, 1 patient from cardiovascular complication,
and 2 patients from sudden unexplained death. In conclusion, there is a
difference in children and adults in hemolytic uremic syndrome in etiologic
factors, but there are no differences in clinical manifestations and labora-
tory findings. Intensive care with close observation including early dialysis
is essential for patient survival.
N-Acetyl.fi-D-glucosaminidase activity in patients with nephrotoxicity
induced by non-ionic low-osmolar contrast media. J.S. Lee, J.H. Park D.J.
Oh, KG. Chul, E. T. Kang, and S.H. Yu, Department of Internal Medicine,
College of Medicine, Chung Ang University, Seoul, Korea. Since the late
1980s it has been claimed that contrast media-induced nephrotoxicity
(CMN) was reduced with the non-ionic low-osmolar contrast media (CM).
Incidence of CMN is over a wide range because there are no reliable
diagnostic criteria. The commonly used diagnostic tools for nephrotoxicity
are creatinine levels in blood, measurement of N-methyl-/3-D-glu-
cosaminidase (NAG) activity and protein analysis in urine by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). We
investigated whether the NAG activity could be used as an indication of
CMN. We studied 32 patients with normal renal functions (mean age 58.7;
M:F = 23.9). We assayed their serum concentrations of creatinine, urine
NAG activities and SDS-PAGE profiles for 5 consequent days after
exposure to CM. The results are as follows: NAG increased in 19 patients
(59.4%) and did not increase in 13 patients (40.6%). From day 1 to day 4,
NAG activities increased significantly in comparison to their pre-exposure
activities (P < 0.05). Serum creatinine increased either more than 50% or
at least 1 mg/dl than the pre-exposure levels in 5 patients (15.6%) and did
not in 27 patients (84.4%). NAG activities significantly increased from day
1 to day 4 in the former group and from day ito day 3 and day 4 in the
latter group (P < 0.05, P < 0.1). Serum creatinine increased either more
than 20% or at least 0.3 mg/dl than the pre-exposure levels in 13 patients
(40.6%) and did not in 19 patients (59.4%). NAG activities increased
significantly from day 1 to day 3 in two groups (P < 0.05). Serum
creatinine increased in only 25% (sensitivity) of the patients with LMW
protein in their urine and did not increase in 90% (specificity) of the
patients without LMW protein in their urine (50% or 1.0 mg/dl). The
sensitivity and specificity of creatinine level were 33.3 and 55% (20% or
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0.3 mg/dl) with the detection of LMW protein upon SDS-PAGE. NAG
activity revealed 76.9% of sensitivity and 52.6% of specificity. We con-
cluded that urinary NAG activity can be a useful indication for contrast
media-induced nephrotoxicity.
Acute renal failure of unidentified etiology following extracorporeal
circulation for bypass of heart and lung. H.J. Kim, YK Yoo, C.H. Park,
CM. Kang, H.C. Park, YH. Kim, and HO. Jee, Departments of Internal
Medicine and Thoracic Swge,y, Hanyang University College of Medicine,
Seoul, Korea. We experienced a recent outbreak of 5 cases of acute renal
failure (ARF) following cardiac operation in the intensive care unit (ICU),
which required extracorporeal circulation for bypass of heart and lung
through operation. Review of hospital records showed 117 operations of
the same type in the last year, and 4 out of 5 cases of ARF occurred in
March and April, 1994. ARF was noticed within 24 hours after surgery
with rapid elevation of serum creatinine and oliguria. Search for the
documented hypotensive episodes during pen-operative period, exposure
for the nephrotoxic anesthetic agents or antibiotics, and hemodynamic
evidence including laboratory data for prerenal azotemia, i.e. volume
contraction, failed to find any underlying causes of ARF in these 5 cases.
All 5 patients were characterized by excessive bleeding of external
thoracotomy operation sites with coagulopathy (prolonged PT and PTf)
and thrombocytopenia with requirement of blood or plasma replacement
as needed. Urinalysis showed microscopic hematunia with occasional RBC
casts. Though elevation of serum indirect bilirubin and LDH was concur-
rently observed with initial phase of ARF, no other discernible evidence
was present for either DIC or acute tubular necrosis related to hemoglo-
binuria. Furthermore, absence of schistocytes on peripheral smear and
relative benign clinical course were unlikely for the diagnosis of hemolytic
uremic syndrome or thrombotic thrombocytopenic purpura. All 5 cases
were treated conservatively for ARF within the ICU, and 3 out of 5 cases
required acute dialysis for 2 to 12 days. All 5 patients recovered eventually
with the change of serum creatinine to pre-operative basal levels within 3
weeks. The underlying etiologies for ARF of these 5 cases, suggestive of
glomerulonephritis, remain unidentified so far but associated factors with
extracorporeal circulation for bypass of heart-lung and hemolysis would be
considered for further clarification of them in addition to renal biopsy if
clinically allowable.
Analysis of 250 cases of rhabdomyolysis. H.Y. Kim, S.O. Cho4 S.J. Shin,
YK Kim, B.G. Han, S.J. Park, AR. Hong, and KH. Lee, Department of
Internal Medicine, College of Wonju Medicine, Yonsei University, Wonju,
Korea. We analyzed the etiologic factors and clinical processes of 250 cases
of rhabdomyolysis. (1) The patients consisted of 196 males and 54 females
with a mean age of 38.9 18.0 years. (2) The etiologic factors of
rhabdomyolysis were as follows: 154 cases of multiple trauma (61.6%), 15
cases of alcohol abuse (6.0%), 14 cases of seizure, 12 cases of shock, 11
cases of metabolic derangement, 9 cases of infection, 8 cases of carbon
monoxide intoxication, 6 cases of drug intoxication, 5 cases of snake bite,
4 cases of burn injury, 3 cases of vessel obstruction, 3 cases of muscle
disease, 1 case of voluntary severe exercise, and 5 cases of unknown cause.
(3) Among the 208 patients except patients not being followed-up, 34
patients (16.3%) developed acute renal failure (defined as a serum
creatinine of 3.0 mg/dl or more) and 16 of these patients (47.1%) died of
pulmonary edema, sepsis and underlying etiologic diseases themselves.
Eight patients had oliguria on admission and 4 of them needed hemodi-
alysis. (4) Twenty-seven patients (10.8%) in the present study died. The
causes of death were: respiratory failure due to acute respiratory distress
syndrome (N = 5), pulmonary edema (N = 2), pneumonia (N 1), sepsis(N = 5), and the underlying etiologic diseases themselves (N = 14).
Role of Ca2 in oxidant-induced cell injury to rabbit renal proximal
tubules. YK Kim, YH. Kim, J.S. Woo, and S.H. Lee, Department of
Physiology, College of Medicine, Pusan National University, Pusan, Korea.
Both oxygen free radicals and Ca2 have been implicated in ischemic and
toxic renal tubular cell injury. However, the role of Ca2 in renal cell
injury induced by oxidants has not been documented. Thus, this study was
undertaken to determine whether Ca2 plays a critical role in t-butyl
hydroperoxide (t-BHP)-mediated renal cell injury. We measured the
active accumulation of organic ion, p-aminohippurate (PAM), to evaluate
the functional capabilities of proximal tubules and the release of lactate
dehydrogenase (LDH) as an indicator of plasma membrane damage in
rabbit renal cortical slices. t-BHP reduced the uptake of PAH in a
dose-dependent manner over concentrations of 0.2—2,0 mM with IC50 of
approximately 0.5 mi. Similarly, t-BHP increased LDH release as well in
a dose-dependent fashion. When slices were treated with t-BHP in
Ca2-free medium or in the presence of verapamil or lanthanum, LDH
release was significantly reduced. Buffering intracellular Ca2 with 1,2-
bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTAJAM), a
membrane permeable Ca2 chelator, caused significant reduction in LDH
release in the slices treated with t-BHP. In contrast, the effect of t-BHP on
PAH uptake was not affected under the same circumstances. The effect of
t-BHP on both PAH uptake and LDH release was almost completely
prevented by each 1 ms of dithiothreitol or glutathione. These results
suggest that t-BHP-induced impairment of active uptake of PAM is not
associated with Ca2 accumulation in rabbit renal cortical slices, while
plasma membrane damage may be mediated by increased intracellular
Ca2t Furthermore, these results indicate that LDH release is not a
sensitive index of cell viability in rabbit renal proximal tubules.
Effect of cisplatin on the epithelial transport system (Na-dependent
hexose transport in LLC-PK1 cells). S.K Lee, J.Y. Kim, KR. Kim, T.H. Vu,
and YS. Park, Departments of Otolaiyngology and Physiology, Kosin Medical
College, Pusan, Korea. Cis-dichiorodiammine platinum II (Cisplatin), an
effective chemotherapeutic agent, induces acute renal failure by unknown
mechanisms. To investigate direct toxic effects of cisplatin on the renal
proximal tubular transport system, LLC-PK1 cell line was selected as a cell
model and the sugar transport activity was evaluated during a course of
cisplatin treatment. The cells grown to confluence were treated with
cisplatin for 60 minutes, washed, and incubated for up to 5 days. At
appropriate intervals, cells were tested for sugar transport using a-meth-
ylglucopyranoside (AMG) as a model substrate. The AMG uptake in cell
suspensions was measured by rapid filtration technique using '4C-AMG as
a tracer. The AMG uptake by the cells treated with 100 sM cisplatin did
not change significantly over the first 24 hours after exposure, but it
decreased progressively after 3 days. The viability of the cell appeared to
be not significantly suppressed with cisplatin of less than 100 LtM, but it
decreased markedly with 150—200 sM. In cells exposed to 100 LM cisplatin
the Na-dependent AMG uptake was drastically inhibited with no change
in the Na-independent uptake. Kinetic analysis of Natdependent AMG
uptake indicated that Vms,, was markedly suppressed, but K,,, was not
altered by cisplatin exposure. Phlorizin binding study suggested that the
number of Na-hexose cotransporters was decreased by cisplatin expo-
sure. The AMG efflux from preloaded LLC-PK1 cells was not altered by
cisplatin treatment. The cellular Na content of LLC-PK1 cells appeared
to be increased after cisplatin treatment, implying that the driving force
for Natcoupled transports was reduced. These results clearly indicate
that cisplatin exposure impairs Na-dependent sugar transport system in
LLC-PK1 cells and suggest that defects in transport function at the luminal
plasma membrane of the proximal tubular cells constitute an important
pathogenic mechanism of cisplatin nephrotoxicity.
Effects of calcium channel blocker on gene expression of c-los and EGF
after ischemic renal injury.J.R. Koo, J.M Kim, YH. Lee, MK Chang, DR.
Cha, W.V Cho, and H.K Kim, Department of Internal Medicine, College of
Medicine, Korea University, Seoul, Korea. Acute ischemic renal failure is an
important clinical entity with increasing tendency, with a permanent loss
of renal function frequently being observed. Recent work has demon-
strated that growth factors play a significant role in mediating the
regeneration process leading to recovery from acute renal failure. The
effect of calcium channel blocker on gene expression after ischemic renal
injury was studied. In these studies, experimental animals were divided
into four groups: Group I (N = 3) was the control without any procedure;
Group II (N = 3) was the sham operation group (bilateral flank incision
and decapsulation were done without renal artery clamping); Group III (N
= 15) was the ischemic renal injury model by right nephrectomy and left
renal artery clamping for 40 minutes; Group IV (N = 15)was the ischemic
renal injury group with nifedipine pretreatment (10 mg/kg, s.c.). In the
ischemic renal failure model (Groups III and IV), rats were further
divided into three subgroups according to reperfusion time, such as 1, 24,
and 72 hours. Total renal RNA was purified by the Chomczynski method.
After the isolation of RNA, electrophoresis was done in a 1% agarose gel
containing 2.2 M formaldehyde, and confirmation of intact RNA was done
by the 18S and 28S ribosomal RNA band. RNA transfer was done by
vacuum transfer system and then the hybridization was performed at 42°C
with isotope labeled probes for 24 hours. Autoradiographs were obtained
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and quantitated by densitometer at 530 nm. The following results were
obtained, and the changes of serum creatinine were as follows: in the
control group 0.9 0.2 mg/dl; in the sham operation group 0.8 0.3
mg/dl; in the ischemic group without nifedipine pretreatment according to
reperfusion time, respectively 0.9 0.3 mg/dl (1 hr), 1.9 0.5 mg/dl (24
hrs), and 3.6 1.4 mg/dl (72 hrs); in the ischemic group with nifedipine
pretreatment according to reperfusion time, respectively 0.5 0.1 mg/dl,
2.4 1.2 mg/dl, and 3.5 2.5 mg/dl. The mean serum creatinine level was
statistically significant between the control and post-ischemic 24, 72 hours
reperfusion groups (P < 0.05). c-fos gene expression was rapidly increased
by renal ischemia with the peak after 60 minutes of reperfusion and then
it rapidly decreased. EGF gene expression was rapidly decreased after the
renal ischemia and slowly recovered in activity after 72 hours of reperfu-
sion. Gene expression pattern of ischemic renal injury with nifedipine
pretreatment was similar to the ischemic group without nifedipine pre-
treatment. From the above findings, c-fos and EGF gene expression are
probably important in the recovery of ischemic renal injury. However,
calcium channel blocker did not influence the gene expression of c-fos and
EGF after ischemic renal injury.
Verapamil attenuates calcium-induced mitochondrial swelling and
respiratory dysfunction. W.S. Koo and R. W. Schrier, Department of Internal
Medicine, Catholic University Medical College, Seoul, Korea, and Depart-
ment of Medicine, University of Colorado Health Sciences Center, Denver,
Colorado, USA. The protective effect of verapamil against hypoxic renal
proximal tubule injury has been demonstrated in association with a
decrease in cellular 45Ca uptake, but may also occur in a calcium free
medium. In view of the latter finding, the possibility was considered that
verapamil may exert direct protective effects at the mitochondrial level,
independent of any effect on cellular calcium influx. Therefore, the direct
effects of verapamil on calcium-induced swelling and respiratory dysfunc-
tion of renal cortical mitochondria were determined. Mitochondrial
swelling was assessed by measuring the change in absorbance at 520 nm
using a Beckman Model 25 spectrophotometer. Mitochondrial oxygen
consumption was measured polarographically in a closed vessel fitted with
a Clark oxygen electrode. Verapamil (100 tiM) significantly inhibited
calcium-induced mitochondrial swelling and partially prevented the asso-
ciated reduction in respiratory control ratio (State 3/State 4, 2.8 0.1 vs.
2.2 0.1; P < 0.001). It was also shown that a phospholipase A2 inhibitor,
dibucaine (100 M), significantly inhibited calcium-induced mitochondrial
swelling. The respiratory control ratio was also higher with dibucaine (2.6
0.03 vs. 1.7 0.2; P < 0.001). In summary, the enhanced mitochondrial
swelling and diminished respiratory function induced by calcium loading
of cortical renal mitochondria were markedly attenuated in the presence
of verapamil. This effect of verapamil was similar to that observed with the
phospholipase A2 inhibitor, dibucaine. These results therefore indicate
that the protective effect of verapamil on hypoxic proximal tubules may
involve effects both on the plasma membrane and the mitochondria. The
effect of verapamil on the mitochondria may be related to inhibition of
mitochondrial phospholipase A2 activation.
A novel mutation in vasopressin V2 receptor gene causing X-linked
nephrogenic diabetes insipidus in a family. HI. Cheong, H. W. Park, IS.
Ha, and Y. Choi, Department of Pediatrics, College of Medicine, Seoul
National University, Seoul, Korea. X-linked nephrogenic diabetes insipidus
(NDI) is a rare disease characterized by the absence of arginine vasopres-
sin V2 receptor responses. Recently, the arginine vasopressin V2 receptor
gene (AVPR2 gene) was cloned, and several mutations in the gene have
been reported in association with NDI. We analyzed the AVPR2 gene in
a family with X-linked NDI. Genomic DNA was isolated from peripheral
blood samples from 11 members of the family. Four overlapping segments
covering the entire coding sequence of the AVPR2 gene were amplified by
polymerase chain reactions (PCR) with the genomic DNA. DNA sequenc-
ing was done using the dideoxy chain termination method after subcloning
of the PCR products into a plasmid vector. We found a mutation in the
AVPR2 gene, common in 4 symptomatic male patients in the family. It
was a novel missense point mutation at the codon 219 CTG to CCG
resulting in a transition of leucine-219, located in the 5th transmembrane
domain of the receptor molecule, to proline. The T to C transition
generated a new recognition site for a restriction endonuclease Sma I.
Three heterozygous female carriers of the mutant gene were confirmed by
digestion of PCR products including the mutation site with Sma I enzyme.
These results provided strong evidence that the mutation was the cause of
NDI in this family.
Clinical aspects of acute focal bacterial nephritis (AFBN). WH. Cho,
S.H. Shon, YL. Kim, D.K Cho, D.C. Park, and J.K Lee, Department of
Internal Medicine, Dongkang Hospital, Ulsan, and Kyungpook University
Hospital, Taegu, Korea. AFBN is a localized bacterial infection of the
kidney presenting itself as an inflammatory mass without drainable pus. It
is being increasingly recognized by current urographic imaging. It is
important not to confuse AFBN with renal abscess or neoplasm, as this
might lead to inappropriate surgical therapy. From January 1992 to
December 1993 in a hospital with a capacity of 600 beds, 24 cases
(F:20,M:4) thought to fulfill the sonographic criteria for AFBN were
reviewed retrospectively. The mean age of 24 patients was 35.7 15.9
years (7 — 78). The duration of preadmission illness was 6.3 5.9 days (1
30). Underlying conditions could be identified in 13 subjects (54.2%):
pregnancy (N = 5), DM (N = 2), renal stones (N = 2), previous urinary
tract infection (N = 2), etc., in order of frequency. Pertinent symptoms
and signs were: chills (100%), flank pain (83%), costovertebral angle
tenderness (100%), fever (88%), pyuria (88%) and leukocytosis (79%).
Urine culture revealed E. coli positive in 10 out of 23 patients tested; one
patient had E. coli positive in blood culture. All patients were admitted
and treated with antibiotics. Fever and flank pain lasted 3.5 0.5 days and
4.1 2.2 days, respectively. No patient underwent surgical procedures.
The duration of hospitalization was 8.9 4.4 days (2 — 20). In conclusion,
AFBN is not an infrequent disease entity, but has a relatively good
prognosis once diagnosed accurately in its early stage. The increased
frequency of the diagnosis of AFBN makes knowledge of the entity, the
appropriate therapy, and the course of illness important.
The effect of pyeloplasty on renal function in children with unilateral
ureteropelvic junction obstruction: Investigation of the split renal func-
tion using ssmTcDMSA renal uptake rate. W. Y. Cho and J.B. Yoon,
Department of Urology, College of Medicine, Pusan National University,
Pusan, Korea. Urinary tract obstruction is one of the most common
abnormalities of the excretory system in children. It is well-demonstrated
that renal function is progressive deteriorated by urinary tract obstruction
and partially recovered by relief of obstruction. But the reports about the
changes of the renal function in contralateral healthy kidney after relief of
unilateral obstruction are rare. Thus, we investigated pre- and post-
operative changes of renal function not only on the obstructed kidney but
also on the contralateral normal kidney in 20 children (10 were younger
than 2 years old) with unilateral hydronephrosis due to ureteropelvic
junction obstruction, using 99mTCDMSA renal uptake rate. A marked
increase in 9smTc..DMSA renal uptake rate was observed in 11 cases
(55.0%) after pyeloplasty on the obstructed kidney. Among them 6
children were younger than 2 years old. In 6 children younger than 2 years,
a pre-operative ssmTcDMSA renal uptake rate in contralateral normal
kidney was markedly decreased. Among them, a marked increase in
post-operative 99mTcDMSA renal uptake rate was observed in 4 cases
(66.7%). In other words, in 4 children younger than 2 years old, a
remarkable increase of 9smTcDMSA renal uptake rate after reconstruc-
tive operation was recognized not only on obstructed kidney but also on
the contralateral normal kidney. This tendency could not be observed in
those older than 2 years old. These results suggest that, in the young
children, the obstructed kidney inhibits the contralateral normal and
compensatory renal growth, and that the relief of obstruction eliminates
this inhibition and causes the renal growth spur in a normal kidney. In
summary, we proposed that it is essential to correct unilateral ureteropel-
vie junction obstruction before two years of age if an improvement of renal
function not only on the obstructed kidney but also on the normal kidney
is to be expected.
Characteristics of acute bacterial nephritis. S.J. Ahn, C. W. Yang, D.C.
Jin, J.Y. Woo, YS. Kim, WS. Koo, E.J. Choi, YS. Jang, Y.S. Yoon, andB.K
Bang, Dept. of Internal Medicine, Medical College, Catholic University,
Seoul, Korea. Acute bacterial nephritis (ABN) is a severe form of acute
infectious interstitial nephritis and is characterized by hypodense lesions
in post-contrast enhancement CT. We reviewed 18 cases of ABN who
were admitted to Catholic Medical Center from January 1991 to March
1994. Results were as follows: (1) Mean age was 53.5 years (27—73) and
male/female ratio was 4/14. (2) Underlying diseases were diabetes (11),
renal cysts (2), renal transplant (1), ureteral stone (1), and liver cirrhosis
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(1). (3) The detection rate of ABN by ultrasonography was 10/17 (59%).
(4) Post-contrast CT findings showed three patterns: Group I (N = 8),
wedge shaped lesion; Group II (N 2), focal mass-like lesion; Group HI(N = 8),multifocal mass-like lesion. (5) The pronounced symptoms were:
pyuria (17/18), fever (15/17), flank pain and bacteriuria (10/18). (6) Acute
renal failure was noted in 4 cases and 1 case showed persistent renal
dysfunction in spite of prolonged antibiotic treatment. In conclusion,
diabetes mellitus was the most common cause of ABN. Because ABN can
cause renal failure which may be persistent, long-term follow-up and
management will be necessary.
Effect of calcium channel blocker on Na-K ATPase during acute
ischemic renal failure. WY. Cho, N.H. Kim, M.K Chang, YH. Lee, D.R.
Cha, J.R. Koo, and H.K Kim, Department of internal Medicine, College of
Medicine, Korea University, Seoul, Korea. The derangement of cellular
calcium homeostasis has been well-known to play an important role in the
pathophysiology of acute ischemic renal failure. With ischemic injury,
Na-K ATPase which is normally located exclusively in the basolateral
membrane moves to the luminal membrane. We investigated the effect of
calcium channel blocker on the changes of renal tubular Na-K ATPase
during acute ischemic renal failure by renal artery occlusion. The exper-
imental animals were perfused with 2% paraformaldehyde and 0.25%
glutaraldehyde as fixatives. All renal tissues were cryocut with 20 im
thickness, and incubated in the presence of a lead ammonium citrate
acetate complex, and observed by light microscope and electron micro-
scope. The results were as follows: (I) Serum creatinine level was 0.44
0.22 mg/dl in the control group, 0.75 0.19 mg/dl in the ischemic group
after 1 hour reperfusion, and 2.94 0.99 mg/dl in the ischemic group after
24 hour reperfusion. The mean serum creatinine level was statistically
significant between the control and the post-ischemic 24 hour reperfusion
groups (P < 0.05). (2) The fine granular reaction product of Na-K ATPase
was present predominantly at the corticomedullary junction in the baso-
lateral area of the thick ascending limb of Henle's loop, distal convoluted
tubule and proximal convoluted tubule in the control group. (3) In the
ischemic group without nifedipine pretreatment, the reaction products
were decreased and focally located in the luminal membrane after 1 hour
reperfusion. There were no significant differences between the 1 hour and
24 hour reperfusion groups. (4) In the nifedipine pretreatment ischemic
group, reaction products were located in the basolateral membrane and
the reactivity was decreased less than the ischemic group without nifedip-
me pretreatment group. From the above findings, Na-K ATPase was
translocated to the luminal membrane from basolateral membrane in
acute ischemic renal failure. This translocation of Na-K ATPase was
related to loss of epithelial cell polarity secondary to loosening the tight
junction in acute ischemic renal failure. The loss of epithelial cell polarity
could be inhibited by administration of calcium channel blockers. During
the early reperfusion phase in the ischemic model pretreated with calcium
channel blocker, Na-K ATPase reactivity was as strong as the control
group, so we suggested that calcium channel blockers could affect the
progression of acute ischemic renal failure.
The clinical experience of staghorn calculi by ESWL monotherapy. H.
Geol, OS. Si/c, S.G. Ta/c, J.K Wo, and Y.J. Han, Dept. of Urology, Dong-A
University Hospital, Pusan, Korea. In the past, staghorn calculi were
managed surgically, but recently with the introduction of ESWL, staghorn
Calculi are managed either by ESWL only or with a combination of
percutaneous nephrolithotomy (PNL) or nephrolithotomy. We reviewed
35 patients with staghorn calculi to determine whether extracorporeal
shock wave lithotripsy (ESWL) monotherapy is a successful alternative to
the classical approaches (open operation vs. percutaneous lithotripsy
alone or with extracorporeal shock wave lithotripsy) using Modulith SL 20
(Electromagnetic Type). The average ESWL treatments per kidney for
complete staghorn calculi were 2.81 sessions, whereas in partial staghorn
calculi it was 3.64 sessions per kidney. The mean hospitalization in patients
treated with Double-J stents is 11.96 days, whereas in those patients
treated without Double-J stent it is 18.53 days. The overall success rate at
long-term follow-up was obtained in 80% in complete staghorn calculi and
84.4% in partial staghorn calculi. Also, the overall success rate in patients
with hydronephrosis was 90.9% whereas in patients without hydronephro-
sis it was 79.2%. The success rate according to stone composition was
100% in MAP stone and uric acid Stone. Of 35 cases, 2 were considered
failures. PNL was performed in 1 after 2 sessions of ESWL and the other
failed to return for further treatment after 1 session of ESWL. The results,
free of residual fragments, were 14% at one month and 48% at three
months. The incidence of post-ESWL complication was much less in
patients treated with Double-i stent in comparison to those treated
without Double-J stent. We conclude ESWL is an effective monotherapy
with minimal complications in the treatment of staghorn calculi and,
especially with the placement of Double-J stent, the complications can be
much reduced with optimal results. In staghorn calculi resistant ESWL
monotherapy, a combination of PNL or nephrolitotomy is mandated.
T-lymphocytic subsets of peripheral blood in primary renal cell carci-
noma. S.D. Lee and J.B. Yoon, Department of Urology, College of Medicine,
Pusan National University, Pusan, Korea. In an attempt to further under-
stand the alteration and biological significance of peripheral T cell subsets
in renal cell carcinoma (RCC), we analyzed T cell subsets using mono-
clonal antibodies and two-color flow cytometry (FCM) in 40 patients with
RCC and 63 cases of adult healthy subjects as the control. All blood
samples were obtained from the veins of patients and control subjects
during the period of January 1991 to March 1994. The results obtained
were summarized as follows: (1) In comparison with RCC patients and
normal controls, preoperatively, there were no significant statistical dif-
ferences in the percentage of CD3, CD4, CD8 cells and the value of
CD4/CDS ratio. (2) In comparison of preoperative period, postoperative
periods of 2 and 6 weeks, there was no significant statistical difference in
the percentages of CD3, CD4, CD8 cells and the value of CD4/CD8 ratio.
(3) When the influence of various tumor factors (stage, grade, cell type
and size) on the T cell subsets in peripheral blood lymphocytes was
examined, a statistically significant decrease in the percentage of CD4 cells
and value of CD4/CD8 ratio was observed along with the aggravation of
tumor grade. An increased percentage of CD8 cell and a decreased value
of CD4/CD8 ratio were observed in sarcomatoid cell type, but tumor stage
and tumor size had no significant influence on the alteration of T cell
subsets. (4) The percentage of CD4 cells and value of CD4/CD8 ratio
tended to be increased in the interferon group as compared with the
non-interferon group. On the basis of these results, we suggested that the
impairment of cellular immune reaction in RCC patients is partially due
to a decreased percentage of CD4 cells and increased percentage of CD8
cells of peripheral blood lymphocytes. The prognosis for the patients who
had high grade was poor, suggesting that changes in the CD4/CD8 ratio
were a sign of the impairment of local immune status associated with
disease prognosis. Also, it is suggested that immunotherapy, such as
interferon in RCC patients, has some benefits on cellular immunity.
Adult nephrotic syndrome in Korea: Analysis of 887 biopsy cases. KH.
Oh, WS. Huh, J.G. Lee, YS. Kim, C. Ahn, IS. Han, S. Kim, H.S. Lee, Yl.
Kim, and J. S. Lee, Dept. of Internal Medicine and Pathology, Seoul National
University Hospital, Seoul, Korea. The total number of biopsies performed
from January 1979 to December 1993 in the Dept. of Internal Medicine at
SNUH was 2476, including 2096 glomerulonephritis (GN) cases. Among
these, 887 patients (42%) were diagnosed as having nephrotic syndrome(NS). Even though these data show that NS composes the major clinical
syndrome of GN in Korea, there have been few reports on this. We
analyzed these 887 patients retrospectively, especially in regard to the
prevalence of clinical and pathologic profiles. The diagnostic criteria for
NS were: (1) 24 hr protein >0.05/kg, or (2) serum albumin <2.5 g/dl and
the serum cholesterol >270 mgldl. Diabetes patients with DM nephrop-
athy or monoclonal gammopathy patients were not biopsied, even though
they have massive proteinuria, and therefore were not included in this
study. (1) The sex ratio of 887 nephrotic patients was 2.1:1 (males 603,
females 284), and the mean age was 32.5 13.2 years. Primary and
secondary nephrotic syndrome were 681 and 178 cases, respectively; 28
cases with rejection and inadequate specimens were not able to be
classified according to the etiology. (2) The pathologic diagnoses of
primary NS were: MCNS (41.1%), MN (21.3%), FGS (17.8%), IgA
nephropathy (8.2%), and MPGN (4.7%). The leading cause of secondary
NS was HBGN (47.2%). The positive rate of HBsAg among NS was
13.5%. Other secondary NS included lupus nephritis (39.3%), amyloidosis
(6.7%), PSGN (2.2%), HSN (1.7%), Fabry's Disease (1 case), cryoglobu-
linemia (1 case), and PAN (1 case). (3) The sex ratios of primary NS were:
MC (3.1:1), FGS (2.5:1), MN (2.1:1), MPGN (2.2:1), and IgA Nephrop-
athy (1.2:1). In secondary NS, male predominance was observed in HBGN
(75%). In lupus nephritis, female predominance was found (75.6%). (4)
Among the patients less than 40 years old, MCNS (48.3%) and FUS
(18.7%) are the most common, but after 40 years MN (44.1%) was more
346 Abstracts
common than MCNS (23.2%). (5) Positive rates of azotemia at the time
of biopsy are 27.1% for MCNS, 48% for FGS, 18.6% for MN, 32% for IgA
nephropathy, and 59.4% for MPGN. Those of hypercholesterolemia are
45.7%, 80%, 73.1%, 52%, and 62.5% for each of the above. Positive rates
of azotemia at the time of biopsy are 34.5% for HBGN, 27% for lupus
nephritis, and 25% for amyloidosis. Those of hypercholesterolemia are
77.4%, 47%, and 83.3% for each of the above. MCNS was the most
common cause of primary NS in Korea. As for the secondary nephrotic
syndrome, except for diabetic nephropathy, HBGN was found in 44%.
Analysis of biopsied cases in patients with glomerular disease. KH.
Kim, J.H. Park, and S.E. Kim, Department of Internal Medicine, College of
Medicine, Dong-A University, Pusan, Korea. To evaluate the incidence and
clinical characteristics of various glomerular diseases (GD) in Korean
adults, we conducted a retrospective study reviewing the histologic
findings and clinical records of the 488 renal biopsy cases of GD. There
were 382 (78.3%) cases of primary GD and 106 (21.7%) of secondary GD.
Among the primary GD, IgA nephropathy (IgAN) was the most common
with 151 (39.5%) cases, followed by 123 (32.2%) of minimal change
nephrotic syndrome (MCNS), 34 (8.9%) of membranous glomerulone-
phritis (MGN), 23 (6.0%) of membranoproliferative GN type I (MPGNI),
and 21(5.5%) of focal glomeruloscierosis (FGS) in the order of frequency.
In the secondary GD group, HBsAg positive cases were 49 (46.2%), and
the rest was 35 (33.0%) of lupus nephritis (LN), 7 (6.6%) of diabetic
nephropathy, and 3 (2.8%) of Henoch-Shonlein purpura. Out of 162
IgAN, 151 (93.2%) cases were idiopathic: focal GN in 70 (48.6%), diffuse
mesangial proliferative (DMsPGN) in 40 (27.8%), minor glomerular
abnormality in 29 (20.1%), and sclerosing GN in 5 (3.5%) cases. In 11
cases of systemic disease-associated IgAN, there were 7 I-IBV surface
antigenemia, 2 liver cirrhosis, 1 alcoholic liver disease, and 1 thin
glomerular basement membrane disease. The frequent events causing
medical attention in patients with IgAN were gross hematuria (32.6%),
urinary abnormality on routine check (23.2%), and edema (17.4%), but
only 24% of patients had true edema and hypoalbuminemia. In the
idiopathic nephrotic syndrome group (INS, total 203 cases), the preva-
lence of each disease and the incidence of clinically overt NS on admission
were 60.6%, 16.7%, 11.3%, 10.3%, and 1% and 94%, 71%, 65%, 81%, and
100% in MCNS, MGN, MPGNI, FGS, and MsPGN, respectively. Serum
HBsAg was positive in 40% of MPGNI, 27.3% of MGN, and 5.6% of
IgAN. According to WHO classification, the histologic findings of LN (35
of 106 cases, 33.0%) were type IV in 48.6%, Yin 28.6%, and each of II and
III in 11.4%. Conclusions: (1) IgAN is the most common primary GD.
Thus, gross hematuria or abnormal urine findings on routine examination
should be considered as highly suggestive of IgAN. (2) MCNS is the most
common cause of INS in Korea. (3) HBV seems to play a role in the
pathogenesis of MPGNI and MGN, but not in IgAN. (4) In secondary
GD, SLE is an important systemic disease requiring renal biopsy.
Analysis of 2,096 renal biopsy cases of glomerulonephritis in adults.
YK Oh, S.J. Lee, H.J.Jin, KW.Joo, Hi. Yun, C.Ahn,J.S. Han, S. Kim,J.S.
Lee, H.S. Lee, and Yl. Kim, Dept. of Internal Medicine, and Dept. of
Pathology, Seoul National University Hospital, Seoul, Korea. Glomerulone-
phritis in adults is known to have diverse causes, pathology, and clinical
features according to gender, age, and people. There have been few
demographic data about adult GN on the basis of pathology in Korea. We
reviewed 2,476 cases of renal biopsy from January 1979 to December 1993
in SNUH and analyzed the age and sex distribution, cause, pathology, and
clinical findings of adult GN. A modification of Churg's method (1982)
was used for classification, sono-guided percutaneous biopsies were done,
and the specimens were observed with LM, EM, and IF. Diabetes patients
with DM retinopathy or monoclonal gammopathy patients were not
biopsied, even though they have massive proteinuria, and therefore were
not included in this study. (1) The mean age at the diagnosis was 33.6 years
(range 15—81), and the male to female ratio was 1.3:1. There were primary
GN (1,545 cases) and secondary GN (551 cases). (2) The pathologic
findings of primary GN were minimal change (27.8%), IgA nephropathy
(22.2%), membranous nephropathy (14.2%), focal glomerular sclerosis
(12.8%), MPGN (3.8%), and others (19.2%) in descending order, and
mean ages were 29.1, 31.3, 41.3, 31.3, and 31.6 years. The incidences of
nephrotic syndrome were 65.1%, 16.3%, 66.2%, 61.4%, and 54.2%. The
most common primary GN types of each age group were minimal change
in 2nd and 3rd decades (41.2%, 35.3%), IgA nephropathy in the 4th
decade (30.0%), and membranous nephropathy in the 5th, 6th and 7th
decades (25.2%, 34.6%, 35.1%). (3) The leading causes of secondary GN
were lupus nephritis (50.8%), HBGN (27.4%), Henoch-Schdnlein nephri-
tis (8.2%), PSGN (4.2%), and others (9.4%), such as amyloidosis,
cryoglobulinemia, Fabry's disease, and Aiport's syndrome. Male predom-
inance was observed in HBGN (M:F 4.6:1), Henoch-Schönlein nephritis
(M:F 1.8:1), and PSGN (M:F 1.3:1). In lupus nephritis, female predomi-
nance was found (M:F 1:7.2). The most common secondary GN types of
each age group were lupus nephritis in the 2nd, 3rd, 4th, 5th and 7th
decades (51.5%, 67.0%, 22.9%, 42.1%), and HBGN in the 6th decade
(34.0%). Mean ages of lupus nephritis and HBGN were 30 and 36 years.
The incidences of nephrotic syndrome were 25.0% and 55.6%. Minimal
change was the most common adult primary GN in Korea, but the
prevalence of membranous nephropathy was higher in old age. In
secondary GN, HBGN was more common in males but lupus nephritis had
a higher incidence in females.
Significance of urinary 132-microglobulin and patterns of proteinuria
determined by SDS-PAGE method in childhood nephrotic syndrome. U.S.
Noh, C. W. Ko, K W. Song, and J.H. Koo, Department of Pediatrics and
Clinical Pathology, School of Medicine, Kyungpook University Hospital,
Taegu, Korea. In children with nephrotic syndrome, the presence of
pathologic changes in the renal tubulointerstitial area signifies a poor
response to steroid therapy. Since urinary 32-microglobulin excretion and
tubular proteinuria indicate tubulointerstitial lesion, the present study was
undertaken to determine the significance of these parameters in relation
to the responsiveness to steroid therapy in nephrotic children. Twenty-
nine nephrotic children were used as study patients. Out of these, 15
children were diagnosed as MCNS and 5 PGN, and in the remaining 9
children, biopsy was not done due to the 1st episode of nephrotic
syndrome. MCNS children were further divided into infrequent relapsers
(IR), steroid dependent (SD), and infrequent relapsers changed from
steroid dependent by cytotoxic therapy (IRSD). Pretreatment urinary
132-microglobulin level was elevated compared to the values of 2nd, 4th,
8th and 12th weeks (88.8 65.5 vs. 31.6 45.8, 27.9 41.3, 17.29 21.82
and 22.7 37.8 jgIg creatinine). However, there was no significant
difference among different groups except in the PGN group, in which its
value was persistently elevated. Patterns of proteinuria analyzed by
SDS-PAGE method showed glomerular selective in 3 and glomerulotu-
bular nonselective in 26 cases. In summary, the present study indicates that
the urinary l32-microglobulin and patterns of proteinuria determined by
SDS-PAGE method are not useful indicators for the prediction of steroid
responsiveness in children with nephrotic syndrome.
Effects of steroid, cyclosporin A and interl'eron-y on the Fc€RII
expression in childhood minimal change nephrotic syndrome. B.S. Cho,
CE. Lee, and KH. Pyun, Dept. of Pediatrics, College of Medicine, Kyung
Hee University, Genetic Engineering Research Institute KIST, Seoul, Korea.
We have reported that peripheral B cells of patients with childhood
MCNS express elevated levels of type II IgE receptor (FceRII), and that
their T cells induce higher levels of IL-4 mRNA expression than those of
normal and disease controls, which in turn correlated well with elevated
serum IgE, soluble Fc€RII and membrane Fc€RII. However, mRNA
expression levels of IFN-y were similar among MCNS, normal and disease
controls. In in vitro cultures, IL-4 efficiently induced Fc€RII expression on
the MCNS B cell membrane in a dose-dependent manner. Treatment with
methylprednisolone (MP), cyclosporin A (CsA) or interferon-y (IFN-y)
all resulted in the inhibition of the IL-4 induced Fc€RII expression by
these cells in both membrane bound and soluble forms. The degree of
inhibition was greater by MP or IFN-y than CsA. Combination treatment
studies revealed that a combined treatment with IFN-y and MP was the
most effective to result in a synergistic inhibition of the IL-4 induced
FceRII expression at both mRNA level and protein levels. Interestingly,
among MCNS patients receiving a steroid therapy, those who responded
with a clinical remission demonstrated a noticeable decrease in Fc€RII
levels on their B cells. From these results combination therapy of MP and
IFN-y may be effective in the control of MCNS through the inhibition of
IL-4 activities as manifested by down-regulation of the IgE receptor.
Prognostic value and histologic correlation of sonography in childhood
nephrotic syndrome. H. W. Cheon, KH. Yoo, and YS. Hong, Department of
Pediatrics, Korea University Hospital, Seoul, Korea. This retrospective case
review of 69 patients who showed proteinuria over 2 g per day at the time
of presentation was designed to evaluate the prognostic value and
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histologic correlation of sonography. Between January 1992 and February
1994, 69 patients were admitted to Korea University Hospital with
proteinuria over 2 g per day. Their ages ranged from ito 15 years (median
8 years); 49 were male, 20 female. In each patient renal ultrasound
examination was performed with DIASONICS SPA 1000 (California,
USA) at the time of presentation. We reviewed interstitial edema,
interstitial fibrosis, tubular atrophy, global sclerosis or inflammatory cell
infiltrate on biopsy reports. Renal biopsy was done in 46 cases. The renal
diseases included in this population were: minimal change disease (N =
20), focal segmental glomerulosclerosis (N = 7), membranous glomeru-
lonephritis (N = 2), membranoproliferative glomerulonephritis (N = 1),
Henoch-SchOnlein purpura nephritis (N = 6), IgA nephropathy (N = 5),
post-streptococcal glomerulonephritis (N = 2), systemic lupus erythema-
tosus (N = 1), and Alport disease (N = 2). In this group there was a
significant correlation between increased echogenicity and global sclerosis
or tubular atrophy (P < 0.05), but there was no correlation between
increased echogenicity and interstitial fibrosis, tubular atrophy, and in-
flammatory cell infiltrate. In primary nephrotic syndrome proven by renal
biopsy (N = 27), there was no correlation between the increased echoge-
nicity and the interstitial edema, interstitial fibrosis, tubular atrophy, or
inflammatory cell infiltrate. But there was a significant correlation be-
tween increased echogenicity and corticosteroid resistance in primary
nephrotic syndrome (P < 0.05). We conclude that increased renal
echogenicity at the time of presentation is a possible indicator of
corticosteroid resistance in primary nephrotic syndrome and the increased
renal echogenicity in patients with proteinuria may be due to tubular
atrophy or global sclerosis.
A comparative study on the effect in bone metabolism and efficacy of the
therapy with prednisolone and deflazacort in childhood nephrotic syn-
drome: A preliminary report. MJ. Kwon, and P.-K Kim, Department of
Pediatrics, Yonsei University, College of Medicine, Seoul, Korea. The rate of
remission induction with initial steroid therapy in children with minimal
change nephrotic syndrome is known to be above 90%, of which 40% is
frequently the relapsing type. In the steroid dependent type, significant
side effects occur during the course of therapy in osteoporosis, growth
retardation, obesity, Cushing syndrome, and diabetes mellitus. Osteopo-
rosis induced by steroids is well-explained by the inhibition of parathyroid
hormone action resulting in malabsorption of calcium ion in bowel,
inhibition of calcium binding protein in intestine, and increased urinary
excretion of calcium salts. By binding to steroid receptor deflazacort, an
oxazoline derivative of prednisolone, anti-inflammatory and immune
suppressive effects are exhibited, but decreases in urinary calcium excre-
tion has less effect on bone resorption. It also decreases incidence of
osteoporosis by a lesser effect on osteoblast activation. Thus, we investi-
gated 15 patients who need long-term steroid therapy, due to nephrotic
syndrome, to see the efficacy, safety, and effect of deflazacort on bone
metabolism. The 24 patients had been diagnosed as idiopathic nephrotic
syndrome and were divided into two groups who received classic pred-
nisolone and deflazacort treatment. The physical examination, blood
chemistries, urinalysis, bone densitometry and onset of remission were
compared. Among them, 12 cases were recurrent diagnosed minimal
change nephrotic syndrome by percutaneous needle biopsy of kidney.
Serum level of albumin, cholesterol, IgG, IgA, 1gM, 24 hour urine
collection protein and selective protein index were compared and there
was no statistical significance. Among the 15 patients who were under
deflazacort therapy, 1 was steroid resistant minimal change nephrotic
syndrome and failed to meet remission. The remaining 14 patients met
remission after an average 12 days. There was no statistical significance in
the steroid and the deflazacort group in onset of remission and laboratory
parameters. In conclusion, we report the efficacy of defiazacort on children
with nephrotic syndrome to be the same as prednisolone. Further inves-
tigation is in progress to find out the effect of deflazacort on bone
metabolism with the bone densitometiy, serum level of osteocalcin,
cortisol and parathyroid hormone and daily dietary intake of calcium.
Minimal change nephrotic syndrome associated with Clq nephropathy.
I. Joo, S.B. Park, W. W. Lee, H. C. Kim, S.P. Kim, and E.S. Chang,
Department of Internal Medicine, Pathology, Keimyung University School of
Medicine, Taegu, Korea. We reported the clinical outcome of twenty
patients who developed a minimal change nephrotic syndrome associated
with Ciq nephropathy. Clq nephropathy is characterized by extensive,
predominantly mesangial, glomerular localization of Clq in patients with
no evidence for systemic lupus eiythematosus. Patients associated with
systemic diseases, infectious diseases, chronic inflammatory diseases,
neoplastic diseases, connective tissue diseases, and HB5Ag carrier were
excluded from the present study. Patients with only scant mesangial Clq
and no large mesangial dense deposits were not included in the Clq
nephropathy category. Clq nephropathy was confirmed in each biopsy by
conventional immunohistology. Only Clq deposits were demonstrated
within the glomerular basement membrane and mesangium in 6 patients
(Group I). In these patients, mean intensity of Clq immunostaining was
1.0+. On presentation the mean urinary protein loss was 11.6 g/day (range
4.9—23.8). Average serum cholesterol and serum albumin levels were 434
mg/dl (range 352—546) and 1.7 gIdl (range 1.0—2.5), respectively. Four
patients of Group I had a complete remission of proteinuria with steroid
therapy. Among them, only 1 patient had complete remission of protein-
uria within 4 weeks with steroid therapy, and 3 patients showed delayed
response to steroids after 2 or 6 months. The remaining 2 patients had a
poor response to steroids. In 14 patients, there was equal staining for Clq
and other immunoglobulins (Group II), and mean intensity of Clq and
other immunoglobulins (Group II), and mean intensity of Clq immunos-
taming was 1.2+, and the mean urinary protein loss was 10.9 glday (range
4.2—17.7). Average serum cholesterol and serum albumin levels were 495
mg/dl (range 339—619), 1.7 gldl (range 1.0—2.2), respectively. Twelve
patients of Group II had a complete remission of proteinuria within 4
weeks, 1 patient after 8 weeks, and there was no response in 2 patients. In
these results, we investigated the possibility of Clq nephropathy in
minimal change nephrotic syndrome with less response to steroid therapy
or delayed remission of proteinuria and followed the response of the
steroid therapy, especially in the presence of immune deposits with a
prominent Clq contribution to mesangial area.
Clq nephropathy: Immunohistopathological and clinical evaluation in
563 renal biopsy specimens. YJ. Choi, YS. Yoon, YS. Koo, B.K Kim, S.M
Kim, B.K Bang, and S.!. Shim, Department of Clinical Pathology and
Internal Medicine, Catholic University Medical College, Seoul, Korea. Clq
nephropathy has been sporadically reported since it was first introduced by
Jennette et al in 1985 and has been regarded as a distinct pathologic entity
usually causing nephrotic syndrome. We report 5 cases of Clq nephrop-
athy confirmed by indirect immunofluorescence in 563 renal biopsy
specimens from patients with proteinuria and/or hematuria. Compared
with other complement or immunoglobulins, Clq deposits were most
intensive (mean 3.2+ out of 4+), and were identified predominantly in the
mesangial area. Light microscopically, the lesions showed mild mesangial
hypercellularity (i case), moderate mesangial hypercellularity with (1
case) or without (2 cases) focal segmental and global sclerosis, or
mesangial proliferative glomerulonephritis (1 case). Ultrastructurally,
three cases had electron dense deposits in the mesangium and/or parame-
sangium. All were males and mean age was 27 (15—42) years. Initially, the
serum creatinine was 1.1 0.2 mg/dl, and the mean urinary protein was
5.0 g/day. All had proteinuria (+ — ++ +), 2 had hematuria, and no one
had hypocomplementemia or antinuclear antibody. Clinical diagnosis was
nephrotic syndrome in three cases, asymptomatic hematuria or protein-
uria in two cases. During mean follow-up period of 12 (2—29) months, the
patients with nephrotic syndrome remitted completely by steroid (2 cases)
or spontaneously (1 case) and asymptomatic proteinuria disappeared (1
case) or decreased (1 case).
Electron
Case
N Clq C3 IgG IgA 1gM
Light microscopy microscopy
dense depositGlomerulus, T-I change
1 3+ 2+ 2+ 1+ 2+ MMH, — 1+;PM
2 4+ 2+ 3+ 0 2+ MoMHcfsgs, + 1+;M&PM
3 3+ 1+ 1+ 0 2+ MsPGN, — 3+:M
4 3+ 0 1+ 2+ 1+ MoMH, + ND
5 3+0 0 0 0 MoMH, — ND
The intensity scale range was 0—4+. Abbreviations are fsgs, focal
segmental and global sclerosis; M, mesangium; MMH, mild mesangial
hypercellularity; MoMH, moderate mesangial hypercellularity; ND, not
done; PM, paramesangium; T-I, tubulointerstitial.
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We conclude that Clq nephropathy is a distinctive variant of mesangial
proliferative glomerulonephritis causing proteinuria with relatively good
prognosis.
Early morphological changes of focal segmental glomerulosclerosis
(FSGS) induced subtotal nephrectomy and puromycin aminonucleotide.
YJ. Kim, KH. Choi, MG. Lee, and YH. Park; Dept. of Pathology, Taegu
Catholic Medical School and Dept. of Pediatrics, Yeungnam University,
Taegu, Korea. This study was conducted to identify the early histological
changes in rat glomerular lesions 8 weeks after renal ablation (PA, 5/6
nephrectomy) and repeat administration of puromycin aminonucleotide
(PAN), which resulted in FSGS. The changes in blood pressure, serum
creatinine and 24 hour urine protein were measured eveiy other week
during the study. Glomerular length and area were estimated by morpho-
metric analysis in sham operation (N = 9), PA (N = 9), and PAN (N =
9) of Sprague-Dawley rats.
BP
mm Hg
Scr
mg/dl
Uprot
mg/day
Initial
Sham 105.6 6.8 0.58 0.22 10.6 5.3
RA 106.7 12.2 0.43 0.2 14.6 7.2
PAN 106.4 9.2 0.48 0.11 15.3 9.3
2 weeks
Sham 103.9 12.9 0.44 0.09 9.6 32b
RA 114.4 8.8 0.56 0.18 65.0 342b
PAN 113.9 6.0 0.54 0.12 80.0 32.0"
4 weeks
Sham 113.3 15.8 0.51 0.13 12.9 5.6
PA 107.8 22.2 0.61 0.18 103.0 42.2"
PAN 115.6 7.7 0.58 0.14 122.7 33.0"
8 weeks
Sham 118.9 22.0 0.70 0.32 15.1 4.3
RA 135.3 18.9" 0.79 0.17 141.8 252b
PAN 125.6 7.7" 0.62 0.12a 137.6 389b
a P < 0.05, compared with initial.
b P < 0.01, compared with initial.
BP, 5Cr and Uprot of RA and PAN were significantly increased at 8 weeks.
Glomerular length (sm) and area (10—s mm2) in RA (166.7 22.9, 18.1
4.3) were increased significantly compared with sham (120.8 18.2, 8.7
1.5) and PAN (120.1 12.2, 8.9 1.3). Histological findings of the
glomerulus were evaluated 8 weeks after RA and PAN. Mesangial
proliferation and glomerular hypertrophy were revealed in RA, but
neither podocyte injury without mesangial change nor glomerular hyper-
trophy were revealed in PAN. The results suggest that early histological
changes by RA and PAN showed different morphological features, such as
glomerular epithelial injury in PAN administration and glomerular hyper-
trophy in subtotal nephrectomy.
Clinicopathologic study in idiopathic nephrotic syndrome associated
with azotemia. NH. Kim, MK Chan& YH. Lee, D.R. Cha, JR. Koo, W. Y.
Cho, ILK Kim, and N.H. Won, Departments of Internal Medicine and
Pathology, College of Medicine, Korea University, Seou1 Korea. Nephrotic
syndrome is clinically characterized by heavy proteinuria, hypoalbumin-
emia, generalized edema, and hyperlipidemia. The natural disease course
and prognosis are variable according to renal pathologic findings, so renal
biopsy is essential in the treatment of patients. The phenomenon of
azotemia in nephrotic syndrome associated with normal renal structure
was first described in detail by Chamberlain et al in 1966. The pathophys-
iologic mechanisms of azotemia in nephrotic syndrome are supposed to be
intravascular volume depletion, renal vein thrombosis, acute interstitial
nephritis and acute tubular injury due to renal ischemia, but the exact role
of these factors was controversial. We examined the clinical features of
azotemia and evaluated the renal pathologic findings in these patients.
The results were as follows: (1) The study population consisted of a renal
dysfunction group (7 cases) and a normal renal function group (31 cases).
The mean age and male to female ratio of each group were: 35 years, 6:1
and 32 years, 23:8, respectively. (2) The mean serum BUN level was 43
20 mg/dl, creatinine 2.36 1.00 mg/dl, blood pressure 136/89 mm Hg in
the patient group associated with azotemia. (3) The mean serum albumin
concentration and urine protein excretion were, respectively, 2.24 0.83
g/dl, 8.67 8.11 g/day in the azotemic patients group, and these values
were not statistically significant different from those in the normal renal
function group. (4) Azotemia was documented an average of 12 days after
onset of nephrotic syndrome and persisted for 3 weeks in the 7 patients in
whom recovery of renal function occurred. (5) Of the renal pathologic
findings in the azotemic group, the most common findings were minimal
change disease in 4 cases, membranoproliferative glomerulonephritis in 2
cases, and focal segmental glomerulosclerosis in 1 case. These results
suggested that minimal change disease was the most common pathologic
finding in the patients with azotemia. The 24 hour urine protein excretion
was not correlated with the development of azotemia and their clinical
course was similar to that of the patients with acute tubular necrosis.
Methylprednisolone (MP) pulse therapy in children with steroid-
resistant nephrotic syndrome. Y.A. Jeon, S.Y. Lee, IS. Ha, ff1. Cheong,
and Y. Choi, Department of Pediatrics, Seoul National University College of
Medicine, Seou1 Korea. Few treatment modalities have been reported to
be useful for steroid-resistant nephrotic syndrome in childhood. Fifteen
Korean children (11 boys and 4 girls) with steroid-resistant nephrotic
syndrome have been treated with MP pulse therapy according to the
protocol proposed by S.A. Mendoza and followed-up for more than 6 (23
9) months. Ten of them were initial nonresponders and 5 children were
subsequent nonresponders. Eight of them had focal segmental glomeru-
losclerosis (FSGS), and the remainder had minimal change lesions
(MCL). The ages at the beginning of the treatment ranged from 1 year 1
month to 15 years 5 months. After 2 weeks of alternate-day treatment, 1
(6%) child got complete remission (CR) and 4 (27%) children obtained
partial remission (PR), while 10(67%) children failed to acquire remission
(NR). After 8 weeks of subsequent weekly treatment, a child who was in
CR relapsed, and 5 of the 10 children in the NR group obtained PR.
Thereafter, 3 children in PR got CR in subsequent treatment. Finally, 3
(20%) and 6 (40%) children obtained CR and PR, respectively, while 6
(40%) children failed to get remission. There was no significant difference
in clinical, laboratory and pathological findings between the responder(CR + PR) and NR group. Five of the responders are in sustained
remission (3—2 1 months) after completion of the treatment, and 2 of the
NR group progressed to ESRD. Infections (6/15), hypertension (2/15) and
arrhythmia (2/15) were the observed side effects of the treatment. With
these data, MP pulse therapy appears to be worth considering in steroid-
resistant nephrotic syndrome in childhood. Further experience with more
patients and longer follow-up seem to be necessary to evaluate this
treatment conclusively.
The clinicopathological features of different types of focal segmental
glomerulosclerosis in adults. SB. Park; I. Joo, H. C. Kim, S.P. Kim, E.S.
Chang, and YJ. Kim, Department of Internal Medicine and Pathology,
Keimyung University School of Medicine, and Department of Pathology,
Taegu Catholic University School of Medicine, Taegu, Korea. Clinicopatho-
logical features of different types of focal segmental glomerulosclerosis
(FSGS) in 47 patients were examined. Of those, 10 patients showed
apparent minimal change nephrotic syndrome with unresponsive steroid
therapy. Early change lesions of FSGS (N = 37) defined that the number
of sclerosing glomeruli was less than 50% of the total examined glomeruli.
Advanced lesions of FSGS (N = 10) were more than 50% of glomeruli.
Early change lesions of FSGS were classified into three categories:
glomerular hypertrophy (GH) type (N = 15), large glomeruli without any
sclerosing lesion; vascular pore (VP) type (N = 15), segmental lesion at
the vascular pore in at least 1 glomerulus; glomerular tip lesion (GTL)
type (N = 7), with a lesion at the tubular origin. The initial renal biopsies
of these early change lesion patients were analyzed morphometrically to
determine the mean glomerular tuft area (GA). All of the early change
lesions showed glomerular hypertrophy, interstitial inflammatory change,
and focal global sclerosis. Hypertrophied glomeruli of early change lesions
had an average GA of 24.3 4.0 x i0 mm2, 49% larger than the
glomeruli from the control glomeruli (P < 0.01). Seven patients (46.7%)
in GH, 9 patients (60.0%) in VP, and 4 patients (57.1%) in GTL had the
typical nephrotic syndrome. Among them, 2 patients in GH, 3 patients in
VP, and 2 patients in GTL, had complete remission of proteinuria with
steroid therapy. Four patients in GH were unresponsive to steroids with
progression to renal insufficiency. These patients subsequently showed
advanced lesions of FSGS at the rebiopsy performed an average of 34.5
months later. Thirty of the patients had normal renal function. However,
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6 patients (40.0%) in GH, 4 patients (26.7%) in VP, 2 patients in GTL,
and 5 patients with advanced lesions of FSGS had renal insufficiency (Sr
> 1.7 mg/dl) initially. We suggest that glomerular hypertrophy accompa-
nied with interstitial inflammatory change and focal global sclerosis is an
important finding of early change lesion of FSGS. Also, the steroid-
unresponsive GH type of early change lesion of FSGS was able to progress
toward advanced lesions of FSGS.
A clinical review of the patients with membranous nephropathy. K T.
Bin, S.S. Kim, MS. Jeong J.H. Lee, K W. Lee, and V. T. Shin, Department of
Internal Medicine, College of Medicine, Chungnam National University,
Taejon, Korea. Membranous nephropathy (MN) is the most common
cause of the idiopathic nephrotic syndrome in adults, in whom it accounts
for about 50% of all cases. Although most cases are idiopathic, some
develop in association with a variety of other conditions, including SLE,
infectious agents, drugs, and malignancy. Therapeutic modality in patients
with MN is still inconclusive. In order to review the clinical findings and
outcome of MN, we retrospectively studied 42 patients with MN who were
admitted to Chungnam National University Hospital from March 1986 to
January 1994. During this period, we performed 523 cases of percutaneous
renal biopsy, and MN accounted for 10.1% of all cases. Among 42
patients, idiopathic MN was 27 cases (64%). Hepatitis B virus associated
MN and membranous lupus nephritis were 8 and 7 cases, respectively.
Mean age of the patients with idiopathic MN was 42 (range 15—78 years)
and ratio of men to women was 1.7:1. Twenty-six (96%) of 27 patients with
idiopathic MN and 14 (93%) of 15 patients with secondary MN showed
nephrotic syndrome. Mean follow-up period of the patients with idio-
pathic MN was 21 months (range 1—92 months) and 20 patients (74%)
were treated with prednisolone and/or cyclophosphamide for more than 6
months. Four patients (20%) showed complete remission of nephrotic
syndrome and 13 patients (65%) had partial remission. Three patients did
not respond and one patient showed a progression to the end-stage renal
failure. Five of the 7 patients with membranous lupus nephritis were
treated with prednisolone and/or cyclophosphamide for more than 6
months, and 4 (80%) of them showed complete remission. Two patients
with hepatitis B virus associated MN were treated with prednisolone. One
patient showed partial remission of nephrotic syndrome and another
patient did not respond. Two patients with hepatitis B associated MN who
were not treated with prednisolone showed partial recovery of nephrotic
syndrome.
Prognostic factors in IgA nephropathy. M.K Chang N.H. Kim, Y.H.
Lee, D.R. Cha, J.R. Koo, WY. Cho, H.K Kim, and NH. Won, Department
of Internal Medicine, Pathology, College of Medicine, Korea University,
Seoul, Korea. IgA nephropathy is a primary renal disease characterized by
prominent mesangial IgA deposition without systemic disease. Recurrent
hematuria and proteinuria are the main clinical manifestations and the
most common renal diseases in patients with recurrent hematuria. The
natural disease course of IgA nephropathy has been thought to be a slowly
progressive disease, but about 20% of patients develop an end-stage renal
disease, so the clinical manifestations and the factors affecting the
prognosis of this disease have very important clinical aspects. We inves-
tigated the clinical features and renal pathologic findings for 43 patients
with IgA nephropathy during the past 4 years. The following results were
obtained: (1) The mean age of the patients was 30 years and 79% were
distributed between 20 to 40 years. The male to female ratio was 1:1. (2)
The most common clinical symptoms were gross hematuria (47%),
microscopic hematuria (21%) and 12 of 43 cases (28%) complained of
associated loin pains. (3) Precipitating factors could be found in 15 cases
(35%) and upper respiratory tract infection was the most common
precipitating factor in 10 cases. The mean duration of symptom onset,
following URI like symptoms, was 6 days. (4) Significant proteinuria(more than 1 g/day) was noted in 10 cases (44%) including 12% of
nephrotic range proteinuria. (5) Mean serum creatinine level was signif-
icantly higher in males, 1.20 0.56 mg/dl, than in females, 0.77 0.18
mg/dl (P < 0.05). (6) Mean serum creatinine level showed a statistically
significant positive correlation with age (r = 0.34), mean blood pressure (r
= 0.71) and 24 hour proteinuria (r = 0.35) (P < 0.05). (7) Twenty-four
hour urine protein was statistically, significantly and positively correlated
with age (r = 0.47) and negatively correlated with mean blood pressure (r
= —0.37) and serum albumin level (r = —0.37) (P < 0.05). (8) Renal
pathologic grading according to ISKDC classification revealed Grade I,
28%; Grade II, 30%; Grade III, 28%; Grade IV, 9% and Grade V, 5%.
Through immunofluorescent microscopy, IgA was found without other
immunoglobulins in 51%; with 1gM 40%; with IgG 2%. (9) Of these cases,
9% progressed to deterioration of renal function during a mean of 17
months follow-up duration. Mean blood pressure and 24 hour proteinuria
of these patients were 152 mm Hg and 4.25 g/day, respectively. Renal
biopsy showed arterial nephrosclerosis in all 4 cases. From the above
results, male sex, old age, mean blood pressure, 24 hour proteinuria and
especially arterial nephrosclerosis, may have a significant correlation with
the prognosis of IgA nephropathy.
Clinical and pathological comparative study of IgA nephropathy and
Henoch-Schbnlein purpura nephritis. S.K Lee, Mi Kwon, J.S. Lee, P.K
Kim, H.Y. Lim, and I.J. Chot, Department of Pediatrics and Pathology,
Yonsei University, College of Medicine, Seoul, Korea. IgA nephropathy
(IgAN) and Henoch-Schönlein purpura nephritis (H-SPN) are both
characterized by mesangial deposition of immune reactants. H-SPN is
accompanied by systemic symptoms such as purpuric skin rashes, abdom-
inal pain and arthralgia. Occasionally, IgAN is not distinguished from
H-SPN in clinical and pathologic aspects. This facts suggests that H-SPN
and IgAN can be genetically related, therefore supporting the notion that
these two disease entities probably share a common pathogenesis. Many
reports revealed that IgAN and H-SPN can progress to nephrotic syn-
drome and chronic renal failure. A few cases reported also involved renal
transplantation. Sixty-two patients were proven to have IgAN and were
observed by clinical, laboratory and pathologic methods and compared
with 56 cases of H-SPN. There was no statistical significance in sex ratio,
duration of disease, incidence of hypertension, renal function and serum
level of IgA. There was a significant difference in the incidence of gross
hematuria at the time of disease onset: 47 cases (76.8%) in IgAN and 13
cases (13.3%) in H-SPN. Urine protein above 1 glday was found in 18
cases (29.0%) in IgAN and 29 cases (5 1.8%) in H-SPN, but there was no
statistical significance. Urine protein above 3 g/day was demonstrated in 8
cases in IgAN and 15 cases in H-SPN. In the 2 groups mentioned above,
gross hematuria was documented in all 8 cases in IgAN but only 5 cases
(33.3%) in H-SPN, making a statistical significance. There was a tendency
of an increase of urine protein in proportion to the pathologic grading in
both disease entities. Immunofluorescent study revealed a statistical
significance by showing a higher rate of fibrinogen deposition in the
mesangium and IgA, IgG and fibrinogen deposition in the capillary in
H-SPN. Among the patients with H-SPN, 1 case received kidney trans-
plantation 8 years after diagnosis. Because the patients with H-SPN
revealed more severe proteinuria and immune deposition in the kidney,
even with one patient experiencing kidney transplantation, continuous
follow-up and active treatment is required in case of nephrotic syndrome.
However, the difficulty is that H-SPN is not distinguished from IgAN if
H-SPN is not confirmed by history and physical examination.
Alpha-interferon therapy in hepatitis B virus (HBV) associated GN.
U.S. Jeon, YK Jeong, H.J. Voon, C. Ahn, J.S. Han, S. Kim, and J.S. Lee,
Dept. of Internal Medicine, Seoul National University Hospita4 Seou4 Korea.
Recently, the results of recombinant alpha-interferon (a-INF) treatment
in chronic HB viral hepatitis showed improvement in serum aminotrans-
aminase levels and clearance of HBeAg. Even though a-INF has been
tried in HBGN, the results were not consistent. We treated 10 HBGN
patients who were diagnosed as HBV associated MN or MPGN with
a-INF. All of them had nephrotic range proteinuria over 6 months,
normal serum creatinine level, and had no other systemic diseases. a-INF,
3,000,000 units, was given intramusculary 6/7 days for 16 weeks and the
therapeutic effects were analyzed at 24 weeks, especially in terms of urine
protein excretion, changes in HBeAg, serum albumin levels, transaminase
levels, and adverse effects. (1) HBeAg disappeared during therapy or
follow-up in 5 patients. In 2, HBeAg seroconversion was transient. In 1,
HBsAg also disappeared transiently. The pathologic diagnoses of these 5
patients were MPGN in 4 and MN in 1. (2) Decrement of proteinuria less
than the level of nephrotic range (0.05 gfkglday) was observed in 6 patients
at the end of the treatment. And 5 out of these 6 patients were
accompanied by the disappearance of HBeAg. (3) The mean level of
serum albumin was changed from 2.6 0.6 g/dl to 2.9 0.8 g/dl in the
HBeAg seroconverted group and from 2.6 0.5 g/dl to 2.7 0.6 g/dI in
others. (4) There were no differences in age, sex, renal pathology, liver
function or renal function between responders and non-responders.
Among serologic markers, RA factor was positive in 2/3 of the responders,
but none of the non-responders (4/4). Sequencial changes of loss of
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HBeAg followed by loss of proteinuria were not observed. (5) All of these
4 responders, who had proper follow-up, showed an increase in the
proteinuria after discontinuation of a-INF; 3 patients had returned to the
nephrotic range at the end of follow-up. (6) The adverse effects of a-INF
were observed in all patients. Mild febrile reaction in early phase
developed in 7, which was relieved spontaneously or by administration of
acetaminophen. Leukopenia developed in 6, which was recovered spon-
taneously after the discontinuation of the therapy. Other adverse effects
were alopecia (3), numbness (3), and skin rash (1). Low dose, short-term
effect of recombinant a-INF in HBGN was analyzed. In short-term
follow-up, decrement in proteinuria associated with HBeAg seroconver-
sion with a-INF treatment was noted.
Nephropathy in patients with rheumatoid arthritis. C.H. Lee, H.J. Kim,
C.H. Par/c, S.Y. Kim, CM. Kang H. C. Par/c, and MH. Par/c, Department of
Internal Medicine and Pathology, Hanyang University College of Medicine,
Seoul, Korea. Studies of renal biopsy tissue have noted a variety of
pathological changes in RA patients with urine abnormalities. Recent
observations seem to indicate the existence of primary renal lesions
associated with RA itself. Because RA patients are frequently treated with
multiple drugs for many years, it is often difficult to distinguish between
disease-associated and drug-associated renal lesions. One cannot exclude
the possibility of two separate but co-existing diseases. To assess the actual
status of renal involvement in RA patients, the present study analyzed 34
RA patients with urine abnormalities. Patients were grouped as follows:
Group 1,7 patients treated with Gold or D-penicillamine and renal biopsy;
Group II, 15 patients with Gold or D-penicillamine and no renal biopsy;
Group III, 12 patients without Gold or D-penicillamine and with renal
biopsy. There were 34 patients, 9 males and 26 females, mean age and
duration of the disease at the time of biopsy 43.3 years and 8.5 years,
respectively. Twenty-two patients had received Gold or D-penicillamine
and urinalysis had been negative for blood and protein before starting
therapy. Isolated hematuria affected 5 patients (22.7%) in Groups I & II
and 6 patients (50%) in Group III. Proteinuria affected 12 patients
(54.6%) in Groups I & II and 3 patients (25%) in Group III. Hematuria
combined with proteinuria affected 5 patients (22.7%) in Groups I & II
and 3 patients (25%) in Group III who had Gold/D-penicillamine therapy.
Urine abnormalities were clinically closely associated with the use of gold
or D-penicillamine, and resolved spontaneously with in a mean of 13
months after stopping the drugs. Renal pathologic findings in 19 cases
demonstrated the following: in Group I, 1 case of normal, minimal change
and mesangial proliferative change, and 2 of minor change; in Group III,
three minor change, three IgA nephropathy, 1 case of minimal and
mesangial proliferative change. These data revealed that the nephropathy
in RA patients with or without goldID-penicillamine therapy was varied
and provided evidence in favor of making renal biopsy with a purpose of
specification of renal pathology.
The first case of Goodpasture's disease in Korea proved with positive
circulating anti-GBM antibodies (Ab). YH. Lee, MK Chan& J.R. Koo,
D.R. Cha, WY. Cho, H.K Kim, and N.H. Won, Department of Internal
Medicine, Pathology, College of Medicine, Korea University, Seoul, Korea.
Goodpasture's disease is characterized by renal symptoms, usually a
rapidly progressive extracapilary proliferative glomerulonephritis without
pulmonary hemorrhage. The pathophysiologic mechanism of this disease
is circulating antibody to glomerular basement membrane antigen (anti-
GBM Ab) binding to kidney and lung. With the development of a
molecular biologic technique, the primary target of anti-GBM antibody is
identified as a 28-kD noncollagenous C-terminus of the a3 chain of type
IV collagen known as NCI. Recently, we experienced the first case of
Goodpasture's disease in Korea, which manifested as rapidly progressive
glomerulonephritis. This patient is a 53 year old female who developed a
generalized edema and anuria. On physical examination, she appeared to
be pale with peripheral pitting edema. Laboratory values were as follows:
hct 24.9%, BUN 62 mg/dl, and Cr 11.8 mg/dl. Serologic markers such as
HBs Ag, CRP, RF, FANA, ANCA and ciyoglobulin were all negative.
Urine analysis showed 3+ for protein and RBC 10—15/HPF. The pa-
tient's course progressively deteriorated, steroid pulse therapy failed to
avert the fulminating condition, and plasmapheresis was done for 3 weeks.
Renal biopsy revealed a diffuse proliferative, crescent glomerulonephritis
(100%) with severe tubulointerstitial edema and inflammatory cell infil-
tration. Direct immunofluorescent staining revealed a linear IgG and C3
deposits along glomerular basement membrane. Circulating anti-GBM Ab
using radioimmunoassay was strongly positive (titer 1:2787 unit). Renal
dysfunction was not restored, and she is currently being treated with
maintenance hemodialysis.
Expression of adhesion molecule in hemorrhagic fever with renal
syndrome. YH. Lee, N.H. Kim, M.K Chang, JR. Koo, DR. Cha, WY. Cho,
H.K Kim, and N.H. Won, Department of Internal Medicine, Pathology,
College of Medicine, Korea University, Seoul, Korea. Hemorrhagic fever
with renal syndrome (HFRS) infected by virus is clinically characterized by
high fever, hypotension, hemorrhagic diasthesis and acute renal failure,
and is spontaneously resolved without significant sequelae. The charac-
teristic pathologic findings are hemorrhagic necrosis of the right atrium,
renal medulla and anterior pituitary gland. In microscopically diffuse
mononuclear cell infiltration, systemic microvascular dilation and capillary
disruption could be found. Recently, the relationship between interstitial
T lymphocyte infiltration and renal dysfunction, including proteinuria, has
been reported. Therefore, this finding suggests that the lymphoid system
may have an important role in the pathogenesis of HFRS. We investigated
the role of adhesion molecules, such as ICAM-I and VCAM-I, in the
pathophysiologic mechanism, such as T cell infiltration, in the renal
interstitium in HFRS. The following results were obtained: (1) The mean
age of patients was 44 years, and the male to female ratio 5:1. (2) The
mean serum BUN and creatinine levels were 61.17 18.41 mg/dl and 7.38
3.34 mg/dl, respectively. (3) Expression of ICAM-I was strongly positive
in glomerular capillary endothelium in 4 cases (80%), and weakly positive
in parietal epithelium and mesangium at 20%, 40% in each. In renal
tubules, 2 cases (33%) showed positive reaction and 3 cases (50%) were
positive in the peritubular capillary wall. ICAM-I expression could not be
found in renal interstitial cells. (4) Expression of VCAM-I was negative in
all cases at renal glomeruli, but 4 of 6 cases (67%) revealed a strong
positive reaction in the renal tubules. In renal peritubular capillary, 1 case
(17%) showed positive reaction and VCAM-I expression could not be
found in the renal interstitium in all cases. (5) In 5 ATN patients (control
group), ICAM-I and VCAM-I expression revealed similar patterns. From
the above findings, strong VCAM-I expression in renal tubules may have
a significant role in the recruitment of T lymphocytes in HFRS, and the
role of ICAM-I seems to be less likely. However, the control group in this
study was not comprised of normal persons, and considering various
reports that ICAM-I and VCAM-I are not expressed in normal renal
tubules, a strong positive reaction of VCAM-I at renal tubules in this study
suggests a possibility of role of adhesion molecules in the pathogenesis of
HFRS. Future studies are required to identify the exact role of adhesion
molecules in the pathophysiology of HFRS.
Sequential studies of glomerular crescent formation in rabbits with
anti-glomerular basement membrane (GBM) antibody-induced glomeru-
lonephritis. H.S. Ahn, J. W. Noh, and M.H. Par/c, Dept. of Pathology, College
of Medicine, Hanyang University, and Dept. of Internal Medicine, College of
Medicine, Hallym University, Seoul, Korea. We studied sequential his-
topathologic changes in the anti-GBM antibody-induced crescentic ne-
phritis in the rabbit. Although no glomerular changes were observed on
light microscopic examination, swelling of endothelial cells, parietal and
visceral epithelial cells were observed during electron microscopic (EM)
examination on day 2. At day 7, the inner surface of the GBM was focally
irregular with subendothelial lucent areas. Neutrophils and platelets were
also noted in the capillary lumen. At day 7, early and cellular crescents
were evident. Proteineous materials and some fibrins were noted in the
capillary lumina and Bowman's spaces. Glomerular capillary lumina were
narrowed by swollen endothelial cells and mesangial expansion. Some
lumina contained neutrophils, macrophages, RBCs and fibrin bundles.
The Bowman's spaces contained amorphous proteineous materials and
large globoid masses of fibrin admixed with cellular debris and RBCs
representing rupture of GBM. In 1 case with cellular crescent, elongated
spindle shaped cells, morphologically resembling fibroblasts, were noted
near the basal lamina of Bowman's capsule. At day 14, the glomerular
capillary tufts were damaged and collapsed with wrinlding of GBM. Many
collagen fibrils were noted in the capillary lumen associated with the
detachment of both endothelial cells and epithelial cells from the GBM.
Focal gaps in the basal lamina of Bowman's capsule were noted. There
were fibrin strands, collagen fibrils and mononuclear cells in the periglo-
merular areas. At day 31, irregular thickening and wriniding of GBMs with
narrowing of the capillary lumina were prominent. The Bowman's spaces
were almostly obliterated by many enlarged epithelial cells. Elongated
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spindle shaped cells lining the inner layers of the crescents and/or
concentric layers throughout the crescent were often associated with loss
of basal lamina of the Bowman's capsule. Tubular atrophy, interstitial
fibrosis, and the inflammatory infiltrates were more severe.
Effect of intravenous infusion of gamma-globulin on rabbit kidney. S.D.
Lee, WS. Kwak, C. W. Ko, K U Song, J.S. Kwalç, and J.H. Koo, Department
of Pediatrics, Pathology and Clinical Pathology School of Medicine, Kyung-
pook University Hospital, Taegu, Korea. The use of intravenous immuno-
globulin (IVIG) in various immunologic disorders has been reported to
cause renal damage. However, the extent and mechanism of its nephro-
toxicity have not been studied adequately. The present experimental study
was undertaken to determine the extent and mechanisms of nephrotoxicity
of IVIG given to rabbits. IVIG (IV-Globulin, Green Cross, Korea) was
given in a dose of 3 g/kg through the ear vein. Group I (N = 5) received
IVIG alone. Group II (N = 5) received pretreatment with methylpred-
nisolone (30 mg/kg) and Group III (N = 5) pretreatment with verapamil(0.15 mg/kg) in addition to IVIG. Twelve hours after IVIG infusion,
animals were sacrificed and kidneys were taken for histopathologic
examination. BUN, creatinine and serum K, determined before and 12
hours after IVIG infusion, did not show any significant change. However,
serum Na was decreased significantly (P 0.05) in all 3 groups. PRA,
determined 12 hours after IVIG infusion showed a decreased value
compared to the value of "before" IVIG infusion (12.9 5.7 vs. 3.5 3.4
ng/mI/hr; P  0.05). Analysis of proteinuria by SDS-PAGE method after
IVIG infusion showed mainly tubular non-selective patterns in all 3
groups. Serum prostaglandin E2 by RIA did not show any significant
changes in the studied groups compared to the control. Histopathologic
changes observed in experimental animals were mainly confined to the
renal tubules, showing patchy areas of necrosis. In conclusion, the present
study indicates that IVIG can cause renal tubular necrosis. This nephro-
toxic effect cannot be prevented by pretreatment with methylprednisolone
or verapamil.
The effect of lovastatin on PDGF-induced DNA synthesis of cultured rat
mesangial cells. S. W. Kang, KH. Choi, H.Y. Lee, and D.S. Han, Dept. of
Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Many glomerular diseases are characterized by focal or diffuse mesangial
cell proliferation with accumulation of extracellular matrix, but the precise
mechanisms of these processes are incompletely understood. It has been
postulated that several cytokines are involved in these pathologic alter-
ations; among them, platelet derived growth factor (PDGF) is known to be
the most potent mitogen for mesangial cells. Several recent experimental
studies have provided evidence that lovastatin, an inhibitor of HMG-coA
reductase, can retard the progression of established glomerular disease in
rats and inhibit proliferation of cultured mesangial cells stimulated by fetal
calf serum. In our study, we investigated the effect of lovastatin on DNA
synthesis and cell proliferation of cultured rat mesangial cells stimulated
by PDGF (—BB). PDGF stimulated DNA synthesis of cultured rat
mesangial cells assessed by 3H-thymidine incorporation in a dose-depen-
dent manner, and at a concentration of 25 ng/ml, PDGF caused about a
15-fold increase in DNA synthesis (mean SD, control 1289 499, PDGF
18870 6789 CPM, P < 0.05). Lovastatin-inhibited PDGF-induced
mesangial cell DNA synthesis in a dose-dependent manner, and at a
concentration of 1 gM, it reduced PDGF-induced 3H-thymidine incorpo-
ration by 33% (P < 0.05), and at 10 LM by 78.8% (P < 0.05). There was
no cytotoxic effect of lovastatin on cultured rat mesangial cells up to a
concentration of 10 .LM. In conclusion, lovastatin has an inhibitory effect
on PDGF-induced DNA synthesis of cultured rat mesangial cells, proba-
bly at the cellular level, in addition to its known cholesterol lowering effect.
Lipocortin-1 inhibits proliferation of cultured human mesangial cells.
SB. Kim, SA. Kang, S. 0. Lee, H. W. Kim, S. Park, IS. Park, and D.S. Na,
Depts. of Internal Medicine and Biochemistry, University of Ulsan and Asan
Institute for Life Sciences, Seoul, Korea. Lipocortin-1 (LP-1), a 37 kD
member of the annexin family of proteins, originally evoked interest as
one of the second messengers for the anti-inflammatory actions of
glucocorticoids. Studies have shown that LP-1 mediates growth inhibition
of glucocorticoids in a human lung adenocarcinoma cell line. The presence
of specific LP-1 binding sites (receptor like molecules) on monocytic cells
has been demonstrated. This study was performed to evaluate the effects
of human LP-1 on cultured human mesangial cells (CHMC). LP-1
inhibited CHMC proliferation in a dose-dependent manner as determined
by 3H-thymidine uptake. Growth of CHMC was inhibited up to 88% in the
presence of 5 rg/m1 of LP-1. A similar growth inhibitory activity by LP-1
was observed in platelet-derived growth factor activated CHMC. Flow
cytometly analysis, as well as immunofluorescent microscopy, revealed
specific binding sites on the surface of CHMC. These results support a
hypothesis that LP-1 generates a proliferation suppressive signal(s)
through specific binding sites on CHMC.
A study of HS-PG mRNA expression in the kidney of streptozotocin-
induced diabetic mice. YJ. Kwon, H.J. Byun, DR. Cha, WY. Cho, H.J. Pyo,
and H.K Kim, Department of Internal Medicine, College of Medicine, Korea
University, Seoul, Korea. Glomerular heparan sulfate proteoglycans (HS-
PG) are important in modulating mesangial cell proliferation, glomerular
extracellular matrix assembly and glomerular permselectivity. Alterations
of glomerular basement membrance HS-PG have been implicated as an
early biochemical abnormality that may contribute to proteinuria in
diabetes mellitus. This study was done to investigate the alterations of
renal HS-PG gene expression with HS-PG cDNA probe in low dose
streptozotocin (STZ)-induced diabetic mice, an experimental model of
insulin dependent diabetes mellitus, with or without insulin treatment.
Fifteen experimental mice (Group II) were given 40 mg/kg body wt daily
of intraperitoneal (i.p.) STZ from day 1 to day 5; Fifteen experimental
mice (Group III) were given STZ followed by daily 0.6 units of subcuta-
neous (s.c.) NPH injection from day 6 during the entire experimental
period, and 9 control mice (Group I) received daily i.p. saline from day 1
to day 5. Control and STZ treated mice were checked for blood sugar
levels at day 0, 14, 28, and 56, and were sacrificed at day 0, 28 and 56.
mRNA from the whole kidney for HS-PG was quantitated by Northern
blot analysis. At days 14, 28, and 56, significant increases in the level of
blood sugar were found in the STZ mice (Groups II and III) compared to
those in controls (Group I). At days 28 and 56, Northern blot analysis
revealed decreased steady-state mRNA levels for HS-PG in the STZ
animals (Groups II and III) compared to those in controls (Group I).
Significant differences in Northern blot analysis at days 28 and 56 were not
found between the STZ mice (Group II) and the STZ mice with insulin
treatment (Group III). These results suggest that a reduction of renal
HS-PG gene expression is an early important factor in the pathogenesis of
diabetic nephropathy in STZ diabetic mice and insulin has no effects on
amelioration of changes in renal HS-PG gene expression of mRNA
extracted from the whole kidney in STZ diabetic mice.
Non-isotopic in situ hybridization for the detection of TGF-p mRNA in
diabetic rats. D.C. Han, S. Y. Jin, S. W. Cho, MK Cha, MS. Park, S.D.
Hwang, and H.B. Lee, Hyonam Kidney Laboratory and Dept. of Pathology,
Soon Chun Hyang University, Seoul, Korea. Cytokine mRNA expression in
renal tissue in different forms of renal injury has mainly been studied in
isolated glomeruli by Northern blot hybridization. This method may result
in the degradation of mRNA during isolation of glomeruli and has the
disadvantage of being unable to localize the site of mRNA expression.
Recently, non-isotopic in situ hybridization using biotin or digoxigenin has
been shown to be a simpler method for the detection of mRNA in
different tissues. TGF-3 appears to have an important role in renal injury
in diabetic nephropathy. To evaluate the usefulness of a non-isotopic in
situ hybridization method for the detection of mRNA expression in
diabetic kidney, we studied TGF-/3 mRNA expression in streptozotocin-
induced diabetic rats using digoxigenin. TGF-f3 probe was labeled with
digoxigenin during PCR. Hybridization was carried out for 12—16 hours at
37°C and washed with SSC for 3 hours. TGF-13 mRNA was noted in the
glomeruli 20 days after the induction of diabetes mellitus. TGF-13 mRNA
expression was markedly suppressed by insulin treatment. There was no
expression of TGF-f3 mRNA in the interstitium or tubular epithelium. In
the normal and RNAse treated diabetic rat kidney, TGF-f3 expression was
not detected. Conclusion: in situ hybridization using digoxigenin is a safe
and rapid method and has an additional advantage of being able to locate
the site of mRNA expression within the kidney.
High glucose induced lipid peroxidation in the isolated rat glomeruli.
II. Ha, S.J. Yoon, and KH. Kim, Department of Pharmacology, Yonsei
University College of Medicine, Seoul, Korea. Our previous study indicated
that oxidative stress is involved in the process of diabetic nephropathy. We
therefore examined whether high glucose per se can increase oxidative
stress in the isolated rat glomeruli, using lipid peroxides (LPO) as an
index. Further involvement of the protein kinase C (PKC) system, which
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has a modulatory role in lipid peroxidation and is activated by high
glucose, was investigated. Glomeruli were isolated from male Sprague-
Dawley rat kidneys utilizing a standard sieving method and incubated in
RPMI-1640 media with or without addition of 20 mivi glucose. The levels
of LPO in the gionieruli exposed to different concentrations of glucose for
1 or 48 hours were quantitated by malondialdehyde-thiobarbituric acid
adduct formation using tetraethoxypropane as a standard. LPO (nmol/mg
of protein) in glomeruli exposed to control or high glucose (HG) were 0.34
0.03 or 0.56 0.06 (P < 0.05) for 1 hour and 0.43 0.09 or 0.76 0.08
(P < 0.05) for 48 hours, respectively. Dimethylthiourea (20 mM), a
hydroxyl radical scavenger, completely blocked the increase of LPO in the
glomeruli exposed to HG not only for 1 hour but also for 48 hours without
altering LPO levels in the glomeruli exposed to control glucose. Pretreat-
ment with PKC antagonists, either 500 p H-7 or 100 nM staurosporine,
prevented an increase of LPO in the glomeruli exposed to HG for 1 hour,
but not in the glomeruli for 48 hours. These data suggest that: (1) elevated
glucose levels per se can cause oxidative stress and augment membrane
lipid peroxidation of glomeruli, and (2) activation of PKC may play a role
in early phase of glucose-induced giomerular lipid peroxidation.
The expression of /31 integrin and ICAM-1 in mesangial cells and its
modulation in glomerulonephritis (GN). C.G. Ihm, J.K Par/c, J.H. Ahn,
T W. Lee, MH. Yang, and M.J. Kim, Dept. of Internal Medicine and
Pathology, College of Medicine, KyungHee University, Seoul, Korea. Cyto-
kine growth factors or reactive oxygen species (ROS) are known as
mediators in GN. /31 integrin and ICAM-1 are suggested to mediate
cell-matrix or cell interaction. However, their expression remains unde-
fined in GN. Therefore, effects of conditioned media (CM) of glomeruli
(G) or mononuclear cells (MNC) on the expression of /31 integrin and
ICAM-1 in mesangial cells and the role of TGF-/3, TNFa, or ROS were
investigated by ELISA, together with [3H1 thymidine uptake in anti-Thyl
GN(MsPGN) and puromycin aminonucleoside nephrosis (PAN). Results:
(1) /31 integrin expression in mesangial cells was significantly higher by the
addition of CM of MNC in MsPGN than in controls (0.122 0.012 O.D.
vs. 0.102 0.015 O.D., P < 0.05), which was completely prevented by 25
pg/mi anti-TGF/3 antibody. By the addition of CM of G, /31 integrin
expression was lower in PAN than in controls (P < 0.05). (2) ICAM-1
expression increased by the addition of CM of MNC, which was prevented
by 50 1d/ml anti-TNFa in 3 groups, while there were no differences
between groups. After adding CM of G it was lower in PAN and MsPGN.
(3) [3H] thymidine uptake by adding CM of MNC was lower in MsPGN
and PAN, which was mitigated by anti-TGF/3 and anti-TNFr. When CM
of G was added, it was less suppressed in PAN compared to controls (P <
0.05). (4) A ROS scavenger (10 ms dimethylthiourea) treatment pre-
vented the increased expression of /31 integrin, induced with CM of MNC
from MsPGN (0.098 0.008 O.D.) (P < 0.05). Conclusions: The
expression of /31 integrin and ICAM-1, and [3H] thymidine uptake in
mesangial cells are regulated by TGFP or TNFa. The increased expression
of /31 integrin mediated by TGF/3 and ROS from MNC in MsPGN and the
decreased expression of /31 integrin and ICAM-1 by CM of G in PAN may
be related to the pathogenesis.
The expression of f31 integrin and intercellular adhesion molecule
(ICAM)-1 in mesangial cells by high glucose and its modulation. C.G.
Ihm, J.K Par/c, J.H. Ahn, T. W. Lee, H.J. Ha, and M.J. Kim, Dept. of Internal
Medicine, College of Medicine, KyungHee University, and Dept. of Pharma-
cology, YonSei University, Seoul, Korea. High glucose has been reported to
increase the synthesis of matrix protein, reactive oxygen species (ROS)
and TGFI3. /31 integrin and ICAM-1 are suggested to mediate the
cell-matrix or cell adhesion. However, their expression in mesangial cells
remains unknown in diabetes. Therefore, the effects of high glucose (25
mM, 48 hr) on their expression and modulation were observed in mesang-
ial cells by ELISA, together with [3H] thymidine uptake. Results: (1) The
expression of ICAM-1 was not different between the normal glucose (NG;
N = 6, 0.101 0.006 O.D.) and high glucose groups (HG; N = 6, 0.104
0.008 O.D.). The treatment with 1 zg/ml TNFa increased ICAM-1
expression by 33% (0.134 0.009 O.D.). (2) The expression of /31 integrin
was significantly higher in HG by 40% than in NG (0.177 0.013 O.D. vs.
0.126 0.012 O.D., P < 0.05), which could not be prevented by treatment
with 25 pg/mi anti-TGF/3 antibody (0.183 0.008 O.D.). (3) [3H}
thymidine uptake was numerically but not significantly lower in HG (74.6
6.0 X io c.p.m.) compared to NG (81.0 10.5 x iO c.p.m.). However,
it became significantly higher after treatment with anti-TGF/3 antibody in
HG than in NG (153.9 19.0 X iO c.p.m. vs. 120.6 13.9 X iO c.p.m.,
P < 0.05). (4) The treatment with a ROS scavenger (10 ms dimethylthio-
urea) could not prevent the HG-induced increases in /31 integrin (0.175
0.010 O.D.). Conclusions: High glucose has no effects on ICAM-1
expression, but increases /31 integrin expression in mesangial cells, which
may be related to matrix accumulation. While [3H] thymidine uptake in
high glucose can be modulated by TGF/3, the high glucose-induced
increase in /31 integrin expression may be mediated by other factor(s).
Expression of ICAM-1 in mouse mesangial cells and cytokines from
mononuclear cells of IgA nephropathy. M.J. Kim, T W. Lee, J.K Par/c, J.H.
Ahn, and C. G. Ihm, Department of Internal Medicine, School of Medicine,
Kyung Hee University, Seoul, Korea. To investigate the possible role of
mononuclear cells and their products in IgA nephropathy, we examined in
vitro expression (0D405) of ICAM-1 with rat mAb to mouse ICAM-1 using
a cell ELISA method in cultured mouse mesangial cells (MC). The MC
were stimulated with TNFa and/or IL-I and PBMC-culture supernatants
from the patients with IgA nephropathy (N = 18), with non-IgA nephrop-
athy (N = 5), and healthy controls (N = 8). The concentrations of TNFa
and IL-i were measured in supernatants by RIA method. The expression
of ICAM-1 on MC in response to various doses (1 pg/mI, 10 pg/mI, 100
pg/mI, 1 ng/ml, 10 ng/ml, 100 nglml, 500 ng/ml) of TNFa, IL-i and TNFa
+ IL-i was studied. Dose-response curves for TNFa showed that ICAM-1
expression is dose-dependent between 1 pg/mi and 100 nglml, and for IL-i
between 1 pg/mI and 1 ng/ml. The expression of ICAM-1 was increased
after co-stimulation with TNFa and IL-i. The MC in a medium only or in
a primary Ab-omitted medium showed a weak ICAM-1 expression
(0D405; 0.2897 0.0425). Addition of PBMC culture supernatants from
IgA nephropathy induced a significant increase of ICAM-1 expression
(0D405; 0.4117 0.0202, P < 0.05) compared than those from non-IgA
nephropathy (0D405; 0.3502 0.0249) and healthy controls (0D405;
0.3094 0.0113). The concentration of TNFa and IL-i in supernatant
from IgA nephropathy (2.715 0.43 ng/ml, 5.36 1.28 ng/ml) was
significantly higher than that from non-IgA nephropathy (1.286 0.173
nglml, 0.515 0.185 ng/mi) and healthy controls (0.964 0.139 ng/ml,
0.437 0.066 ng/ml) and showed a good correlation with the ICAM-1
expression. In conclusion, cytokines released from mononuclear cells
induced the up-regulation of ICAM-1 expression on mesangial cells in IgA
nephropathy.
Effect of renal artery pressure and norepinephrine on the rate of renal
urokinase production. S.Y. Hong D.H. Yang, H.M. Yang, Dept. of Internal
Medicine and Physiology, Soonchunhyang University Hospital Chunan,
Korea. The effect of changes in renal blood pressure and renal sympathetic
stimulation on the renal urokinase production was evaluated in five female
dogs. The mean urokinase activity was 13.3 2.7 U/mI (range: 10.0—16.0)
in the basal state-i, 8.2 2.7 U/mi (range: 4.4—11.4) in the hypotension
state, 10.6 3.2 U/mI (range: 65—14.4) in the basal state-2, and 15.1 4.8
U/mi (range: 10.2—20.3) in the norepinephrine state. These findings reveal
that the urokinase concentration in the urine decreased as the renal artery
pressure decreased, and returned to the basal level when the renal artery
pressure increased to the basal level. Norepinephrine increased the
urokinase concentration in all cases. Our results suggest that the appro-
priate maintenance of renal artery pressure is necessary for steady renal
urokinase production and that renal sympathetic activity is one of the
stimulants for renal urokinase production.
Effects of L-arginine supplementation on the vascular function in
streptozotocin-induced diabetic rats. K C. Choi, K Yoo, J. Lee, and YJ.
Kang, Departments of Internal Medicine and Physiology, Chonnam Univer-
sity Medical School, Kwangju, Korea. The present study was designed to
investigate whether L-arginine may prevent a vascular dysfunction and
whether responses of a peripheral artery to ATP-sensitive potassium
channel openers are altered in diabetes. Diabetes was induced in rats
(Sprague-Dawley, males, 110—130 g) by treatment with streptozotocin (50
mg/kg, i.p.). Following the treatment, 1 group was supplied with normal
tap water and another supplemented with L-arginine (400 mg/lOU ml) in
the drinking water. They were used for experimentation 12 weeks later. A
group of age-matched rats without streptozotocin treatment served as
controls. Blood glucose concentrations upon decapitation in a conscious
state were 383 21 (N = 6), 434 57 (N = 6), and 63 4 mg/dl (N =
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6) in streptozotocin-treated, streptozotocin-treated plus L-arginine-sup-
plemented and control groups, respectively. Vasocontraction of the iso-
lated thoracic aorta in response to phenylephrine or ultraviolet light was
enhanced and vasorelaxation to acetylcholine or nitroprusside decreased
in the streptozotocin-treated group compared with the control. Vascular
production of cyclic GMP stimulated by acetylcholine or nitroprusside was
significantly decreased in the streptozotocin-treated group. In the L-
arginine-supplemented group, the magnitude of vasocontraction to phen-
ylephrine was normalized, being comparable to that in the control.
L-Arginine supplementation redeemed the degree of vasorelaxation and
cyclic GMP production in response to acetylcholine or nitroprusside. The
degree of vasorelaxation of the tail artely in response to diazoxide, an
ATP-sensitive potassium channel opener, did not differ between the
streptozotocin-treated and control groups. These results suggest that
diabetes causes a vascular dysfunction which may be prevented by
supplementation with L-arginine, through increasing the responsiveness of
the vasculature to produce cyclic UMP.
Central and peripheral pressor effects of nitric oxide synthesis inhibi-
tion in anesthetized rats. KC. Choi, K Yoo, J. Lee, and YJ. Kang,
Departments of Internal Medicine and Physiology, Chonnam University
Medical Schoo4 Kwangju, Korea. The existence of the L-arginine-nitric
oxide (NO) pathway has been established in the central nervous system. A
central role of NO in blood pressure regulation has also been suggested.
The present study was undertaken to determine if the endogenous
L-arginine-NO pathway has separate central mechanisms in blood pres-
sure regulation. Blood pressure and heart rate responses to acute inhibi-
tion of L-arginine-NO pathway were examined in rats (Sprague-Dawley,
males, 200—250 g) anesthetized with thiopental (50 mg/kg i.p.). The right
femoral artery was cannulated to measure arterial blood pressure and the
vein served as an infusion route. An intracerebroventricular (ICV)
cannula was placed in the left lateral ventricle. L-NAME was infused,
either intravenously or intracerebroventricularly using an infusion pump.
Intravenous infusion of L-NAME (40 1u1/min, 10—100 pg/kg per minute)
increased blood pressure in association with decreases in heart rate. ICV
infusion (1.25 ui/min, 10—100 pg/kg per minute) also increased the blood
pressure, which was, however, associated with increases in heart rate.
L-Arginine (60 g/min, ICV) prevented the blood pressure change in
response to ICV L-NAME. Neither the blood pressure nor heart rate
increase in response to ICV L-NAME was affected by simultaneous
intravenous infusion of saralasin. Hexamethonium treatment, however,
abolished the heart rate as well as blood pressure response to L-NAME.
These results indicate that the endogenous L-arginine-NO pathway has
separate central and peripheral mechanisms in regulating the cardiovas-
cular function. The central effect may not be mediated by activation of the
renin-angiotensin system but, at least in part, by activation of the
sympathetic outflow.
Effects of Ginseng Saponin on activity of renal nitric oxide synthase
after unilatera' nephrectomy in rats. S. W. Han, H. Kim, and S.K Choi,
Department of Urology and Pharmacology, Yonsei University College of
Medicine, Seoul, Korea. Compensatory renal hypertrophy (CRH) replaces
lost renal function by increasing renal blood flow and glomerular filtration
rate to the remaining renal parenchyme. In the long run, it is clinically
important because it can be one of the precursor lesions of glomerulo-
sclerosis, and its exact mechanism has not yet been elucidated. Recent in
vitro studies revealed that nitric oxide in kidney cells, a possible messenger
of growth factors, was related to the CRH. Therefore, nitric oxide synthase
(NOS) might play a vital role in CRH. After CRH was induced by
unilateral nephrectomy, NOS activity, protein and DNA content per unit
wet weight were observed in glomeruli, renal cortex excluding glomeruli
(cortex()), and medulla in rats in sham-operated (SO), unilateral ne-
phrectomy (UNX), SO and Saponin treated, and UNX and Saponin
treated groups. Five days after UNX in 100—140 g male Sprague-Dawley
rats, the remaining kidney was harvested and divided into glomeruli,
cortex and medulla. The NOS activity was measured in each portion by
comparing the conversion rate from 14-L-arginine to 14 C-L-citrulline.
The protein and DNA content per unit wet weight were measured. After
UNX, NOS activity increased in the cortex (P = 0.04) and no significant
differences were noted in glomeruli and medulla. After treatment with
Saponin, in the SO group NOS activity increased in glomeruli and
cortex (P < 0.01), and no significant differences were noted in the
medulla. After UNX, the Saponin treatment did not result in a significant
change of NOS activity in the glomeruli or cortex, but increased in the
medulla (P < 0.01). The protein and DNA content per Unit wet weight
after UNX did not show any significant differences among groups. The
Ginseng Saponin treatment did not result in significant differences in the
protein and DNA content per unit wet weight, except in SO groups, where
DNA content was decreased (P = 0.02). Conclusively, CRH could be
closely related to the chage of the NOS activity in the cortex, and
Saponin increases the NOS activity in the physiological condition and
maintains a near normal activity of NOS in the medulla of CRH. The lack
of change in protein and DNA content per unit wet weight in CRH is
evidence that changes of NOS activity in cortex is a specific finding.
The role of nitric oxide in hemorrhagic fever with renal syndrome. J.H.
Park J.S. Lee, K C. Kwak D.J. Oh, E. T. Kang, and S.H. Vu, Chung-Ang
University Hospital, Seoul, Korea. Hemorrhagic fever with renal syndrome
(HFRS) is the infectious disease caused by Hantavirus. Clinically, it is
characterized by fever, shock, a varying degree of renal failure and a
tendency for bleeding. But the mechanisms by which the virus elicits
clinical shock and other signs are still obscure. We have studied the role
of nitric oxide (EDRF) in 7 severely ill patients with HFRS. Each patient's
sera were assayed for nitric oxide with HPLC. In the febrile phase, nitric
oxide was significantly elevated in comparison to the disease control (167.2
vs. 71.4 mM/liter, P = 0.008). In the hypotensive phase, it decreased
abruptly (73.7 mM/liter) and remained decreased until the early oliguric
phase. In the late oliguric and early diuretic phase, nitric oxide increased
markedly (136.17 vs. 72.4 mM/liter, P = 0.0291) and then decreased
gradually throughout the convalescent phase. We concluded that nitric
oxide had an important role in the pathogenesis and functional alterations
in HFRS.
Renal effects of low-protein diet and anti-hypertensive drugs on the
progression of early chronic renal failure. KS. Kim, WK Yang, KH. Kim,
S. V. Kim, YJ. Kang, and W.J. Maeng Dept. of Pediatrics and Pathology,
College of Medicine, and Dept. of Feed and Nutritional Science, College of
Animal Husbandry, KonKuk University, Seoul, Korea. Chronic renal failure,
once established, tends to progress inexorably to end-stage renal failure.
Experimental evidence for the progressive development of renal lesions in
the remnant kidney after severe renal ablation was provided. In response
to reduction in renal mass, the remaining remnant nephrons initially
compensate through increases in size. Glomerular hypertrophy has been
associated with the development of glomerular injury in models of
reduced renal mass. The synergistic effects of protein restriction and
antihypertensive therapy on the progression of early renal failure in the
excision remnant kidney model were studied. Rats underwent 5/6 nephrec-
tomy and 1 week later, rats were randomly assigned to receive no
antihypertensive therapy, angiotensin converting enzyme inhibitor, enala-
pril (E) nor calcium channel blocker, nicardipine (N). Three groups were
divided into group A and group B, according to maintenance on isocaloric
diets with 18.5% protein (A) and 6% protein contents (B), respectively.
Mesangeal matrix injury score and glomerular size were assessed 4, 12,
and 16 weeks after renal ablation. The protein restriction group showed no
effect on systemic blood pressure. Administration of E or N was associated
with a reduction in systemic blood pressure. The mesangial matrix injury
score was decreased in group B and groups E and N, rather than those of
group A and the no antihypertensive therapy group. Morphometric
analysis showed that glomerular volume was lower in group B than that in
group A, and glomerular volume in group E was not significantly different
from that in group N. In conclusion, protein restriction retards glomerular
injury without affecting systemic blood pressure due to inhibiting compen-
satory renal growth. Antihypertensive drugs, enalapril and nicardipine,
also protect glomerular hypertrophy and attenuates glomerular injury.
However, combined treatment with protein restriction and antihyperten-
sive drugs didn't appear to show a synergistic effect to attenuate glomer-
ular injury.
Serum and urine neopterins in patients with chronic renal disease. S.0.
Choi, KH. Lee, S.f. Shin, B.G. Han, and H.Y. Kim, Department of Internal
Medicine, College of Medicine, Yonsei University, Wonju, Korea. This study
was designed to assess the clinical significance of serum and urine
neopterins by radioimmunoassay in 64 patients with various renal pathol-
ogies and renal functions. Serum neopterin levels in patients with glomer-
ulonephritis with normal glomerular filtration rate (5.3 3.0 nmol/liter),
in those with chronic renal failure before dialysis (40.0 36.2 nmol/liter),
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and in end-stage renal disease patients on dialysis (169.0 81.8 nmol/
liter) were significantly increased compared with the control group (3.6
0.6 nmollliter) (P < 0.05). In 64 cases with renal disease, a strong positive
correlation was demonstrated among the serum neopterin levels, serum
BUN and creatinine concentration (P < 0.0001). The urinary excretion
ratios of neopterin (urinary neopterin/urinaiy creatinine level) in patients
with renal disease were increased compared to controls and significantly
negatively correlated with creatinine clearance (P < 0.05). This study
could not find a significant difference in serum neopterins and urinary
neopterin/creatinine ratios among the histologically different four groups,
which are minimal change glomerulopathy, membranous glomerulone-
phritis, membranoproliferative glomerulonephritis and IgA nephropathy.
These data suggest that in patients with renal disease, the neopterin levels
in serum are closely negatively correlated with glomerular filtration rate
rather than renal pathologic changes, and the urinary excretion of
neopterin may reflect the predominance of increased tubular secretion of
neopterin over the increased glomerular capillary permeability by glomer-
ular injury. However, there is a possibility that significantly higher levels of
serum neopterin in patients with glomerulonephritis than in controls, in
spite of no difference in glomerular filtration rate, may be due to the
increased activity of cellular immunity.
Clinical study of 21 cases of adult polycystic kidney disease. H. Y. Song,
J.E. Kim, W.J. Kang S.K Park; and S-K Kang, Department of Internal
Medicine, Chonbuk National University Medical School, Chonju, Korea.
Adult polycystic kidney disease (ADPKD) is a hereditary disorder trans-
mitted by autosomal dominant gene(s), and characterized by multiple
cysts on kidneys and many other organs. There are about one-half million
patients with ADPKD in the United States, and approximately 10% of
patients on dialysis in the United States have ADPKD. To develop the
profile of ADPKD, we analyzed clinical characteristics of 21 patients
retrospectively. In this series 57% of the patients were in their 5th and 6th
decades of life at the time of diagnosis. The male to female sex ratio was
1:1.6. On admission, symptoms and signs were headache (47.6%), flank
pain (28.6%), palpable kidney (48%), and hypertension (33%). Cysts in
the liver (48%) were the major extrarenal lesions, and there was 1 case of
cysts in the spleen. Thirty percent of patients revealed normal urine
findings on admission. Eight patients were diagnosed as chronic renal
failure on admission: 3 of them underwent dialysis, and 1 of them
underwent renal transplantation. The incidence of positive family history
was only 14.3%. We suspect there are many families with adult polycystic
kidney disease. Therefore, we should place emphasis on early detection
and management of adult polycystic kidney disease.
The effect of aluminum hydroxide administration on serum aluminum
concentration in end-stage renal disease. W.S. Chu, S.Y. Ki, H.K Lim, J.Y.
Lee, YS. Kim, MK Cha, D.H. Yang, and S.Y. Hong, Department of Internal
Medicine, Soonchunhyang University Hospital, Chunan, Korea. It is possible
that the administration of aluminum hydroxide as a phosphate binder
causes aluminum intoxication in end-stage renal disease (ESRD). The
serum aluminum levels were measured after desferrioxamine infusion in
108 ESRD patients who have been dialyzed for more than 6 months. The
total aluminum intake and other clinical variables, such as underlying
diseases, forms of phosphate binder, and performance status, were
assessed by review of the medical records. We evaluated the correlation
among the serum aluminum levels, the total aluminum intake, and the
other clinical variables. The serum aluminum concentration showed a
direct correlation with the total aluminum intake (r = 0.4, P = 0.001).
According to the forms of aluminum intake, the mean aluminum concen-
tration (mg/liter) was 124.8 67.2 in the gel group. The mean aluminum
concentration in the tablet group and the non-administration group were
98.3 53.1 and 73.2 34.5, respectively. The aluminum concentration
was significantly higher in the gel and tablet groups than the non-
administration group (P < 0.05). However, there was no significant
difference from the underlying disease, and the various degrees of
performance status. Other clinical variables were not correlated to the
aluminum level. Our results suggest that the stored aluminum amount is
influenced by the total aluminum intake. Therefore, we recommend that
physicians should be alert to the possibility that aluminum intoxication
may occur in chronic dialysis patients who are taking aluminum-containing
phosphate binders.
of Internal Medicine, DanKook University Medical College, Choongnam,
Korea. Recently, there have been some reports on the activation of
renin-angiotensin axis (R-A axis) by eiythropoietin (EPO). However, the
investigations on the EPO production induced by R-A axis change were
rarely reported. We observed the blockade of the R-A axis with angioten-
sin converting enzyme inhibitor (ACEi) prevent the rise in hemoglobin of
chronic renal failure. In experimental studies, the activation of the R-A
axis and anemia were induced by blood sampling from the inferior vena
cava of 23 Sprague-Dawley rats, but the sampled blood amount of 14 rats
was replaced by normal saline to prevent the activation of the R-A axis.
The serum EPO levels were significantly decreased in the group of rats
replaced by normal saline.
Dec. Hgb/
Exp. mode
gidi
Anemia and
hypovolemia
Serum EPO:m U/mI
Anemia
EPO:mUlml Significance
3.0 318.8 118.7 149.3 103.2 <0.05
2.0—2.9 40.45 8.9 33.3 10 NS
0—1.9 38 36.0 10.3 NS
In clinical studies, 30 patients were divided into 2 groups. Group 1: 15
CRF patients undergoing hemodialysis received ACEi (enalapril). Group
2: 15 CRF patients undergoing hemodialysis didn't receive ACEi as an
antihypertensive drug. The frequency of transfusion per year was signifi-
cantly higher in group 1 as well as in patients with higher doses of ACEi.
In conclusion, we observed a significant increase in the requirement of
transfusion in chronic renal failure patients under treatment with ACEi.
Therefore, continuous administration of ACEi can aggravate the anemia
associated with chronic renal failure.
Bumetanide pharmacokinetics and pharmacodynamics in patients with
nephrotic syndrome. KS. Kim, KH. Lee, I.J. Jang, S.G. Shin, J.S. Han, 5G.
Kim, and J. S. Lee. Department of Internal Medicine, College of Medicine,
KonKuk University, and Department of Phannacology and Department of
Internal Medicine, Seoul National University College of Medicine, Seoul,
Korea. This study was performed to evaluate the existence of diuretic
resistance of bumetanide in patients with nephrotic syndrome and to
elucidate the mechanism of diuretic resistance in patients with nephrotic
syndrome using a pharmacokinetic/pharmacodynamic model. A single
oral dose of I mg bumetanide was administered in each of the 8 normals
and 8 patients with nephrotic syndrome. After administration of bumet-
anide, the blood and urine samples were collected simultaneously from the
normals and patients with nephrotic syndrome whose fluid balance were
maintained throughout the sampling period. For pharmacokinetic and
pharmacodynamic analysis, plasma concentration of bumetanide, urinary
excretion rate of total and free bumetanide, urine flow rate, and urinary
excretion rate of electrolytes were determined. The pharmacodynamic
characteristics were analyzed with Hill's, Emax or linear model. There
were no differences in pharmacokinetic parameters between normals and
patients with nephrotic syndrome. The urine flow rate, excretory rate of
sodium and chloride to the urinary excretory rate of free bumetanide were
best fit on the linear model in patients with nephrotic syndrome, but best
fit on the Emax or linear model in normal subjects. The mean values of
urine volume, sodium and chloride amount excreted in 24 hour urine after
administration of bumetanide were 2061.03 747.4 mg, 169.6 118.4
mEq, 176.0 107.8 mEq in patients with nephrotic syndrome and 6281.2
974.6 ml, 326.0 49.3 mEq, 334.6 39.2 mEq in normal subjects,
respectively. The clockwise hysteresis patterns were evident in the phar-
macodynamic plot for urine flow rate, urinary excretion rate of sodium and
chloride versus urinary excretion rate of free bumetanide, which implied
development of acute tolerance to bumetanide in both normals and
patients with nephrotic syndrome. The ratios of urine volume, sodium and
chloride/bumetanide excretion in 24 hour urine after administration of
bumetanide in patients with nephrotic syndrome were significantly less
than those of normal subjects. The results suggest that the diuretic
resistance of bumetanide in patients with nephrotic syndrome seems to be
due to the changes of characteristics in the ascending limb of the loop of
Henle as well as the protein binding of bumetanide in the renal tubule.
The aggravation of anemia induced by suppressed renin-angiotensin Metabolic acidosis and anion gap patterns in chronic hemodialysis
axis in chronic renal failure patients. Di. Kim and S.C. Yun, Department patients. H.J. Kim, CI. Sohn, C.H. Park; C.M Kang, and H.C. Park;
Abstracts 355
Department of Internal Medicine, Hanyang University College of Medicine,
Seou1 Korea. Analysis of predialysis metabolic acidosis and anion gap
patterns was performed in 67 stable chronic outpatient hemodialysis
patients (> 1 year) with acetate buffer. The degree of metabolic acidosis
was mild to moderate with mean pH (± SD) 7.33 0.039. Most of the
patients had a pH between 7.300 and 7.39 (82%), with the remainder
between 7.20 to 7.299 (18%). Simple as well as mixed metabolic acidosis
was shown in 49 of 67 (73%) and 18 of 67 (27%), respectively. In
comparison of both groups, the group with mixed metabolic acidosis had
a significantly lower pH (7.29 0.04 vs. 7.34 0.03, P < 0.001) with
higher pCO2 (38.5 3.6 vs. 36.5 3.4, P < 0.005) and anion gap (19.6
4.1 vs. 17.6 2.9, P < 0.05). The "classical" high anion gap of end-stage
renal disease (range, 16 to 29 mEq/liter) was found in 47 of the 67 patients
(70%). However, normal anion gap (range, 10 to 16 mEq/liter) was also
noted in 20 of 67 patients (30%). The linear regression analysis between
anion gaps and total serum carbon dioxide (TCO2) contents didn't show
any significant correlation in all patients as well as the 2 subdivided groups
with high and normal anion gap. Furthermore, only 13 of 67 patients
(20%) were included between 80 to 120% in the ratio of delta anion gap
(dAG) over delta TCO2 (dTCO2). Therefore, the majority of hemodialysis
patients (80%) showed a discrepancy between the degrees of dAG and
dTCO2. A positive correlation between dAG/dTCO2 and dAG in 67
patients was found with 100% of dAG/dTCO2 at 7.5 mEq of dAG: y =
11.8x + 11.3; r = 0.8, P < 0.001. The analysis of unmeasured cations (K,
Ca) and anions (albumin, phosphate) in the calculation of anion gap
(Na-Cl-HCO) between the 2 groups of high and normal anion gap of all
patients as well as 49 patients of simple metabolic acidosis didn't reveal
any discernible contributions to the changes of anion gap. This study
therefore showed that the mixed acid-base balance and normal anion gap
metabolic acidosis is not an exception in chronic stable hemodialysis
patients. Also, the impact of hemodialysis in ESRD patients seemed to
lead the changes in values of unidentified anions besides fixed mineral
acids and/or in those of unrecognized ionic equivalents of plasma constit-
uents.
The characteristics of metabolic acidosis In chronic renal failure. K W.
Joo, G.H. Kim, 5G. Lee, KY. Na, YS. Kim, C. Ahn, J.S. Han, S. Kim, and
IS. Lee, Department of Internal Medicine, Seoul National University and
Hallym University College of Medicine, Seoul, Korea. It has been recently
reported that serum anion gap of acidosis in CRF was usually normal. The
proposed explanations were: (1) The central cause of acidosis of renal
failure is a defect in urinary ammonium excretion and the increased serum
anion gap is largely due to the inability to excrete anions. (2) The
measurement method of chloride ion has been changed to the ion
selective electrode method. In order to ascertain which explanation is
correct, we compared the serum anion gaps and urinary acidification
indices in 5 normal control subjects with ammonium chloride loading and
17 CRF patients with metabolic acidosis. The results were as follows: (1)
Serum anion gap of 5 normal control subjects was 6.0 1.7 mEq/liter
(mean so) and serum anion gap calculated using the chloride value
measured by mercuric-thiocyanate colorimetric method was 15.0 3.4
mEq/liter. Thirteen of the 17 CRF patients showed elevated serum anion
gap, when a reference range of 3—9 mEq/liter (mean 2 SD) was used. (2)
Both serum creatinine and phosphorus levels were significantly elevated in
the patients with increased serum anion gap (10.7 3.1 mg/dl, 7.3 2.3
mg/dl) than those of patients with normal anion gap (5.7 1.5 mg/dl, 4.4
0.3 mg/dl) (P < 0.01). (3) Twenty-four hour ammonium excretion was
markedly reduced both in the 13 patients with high serum anion gap and
the 4 patients with normal anion gap (9.5 6.1 mmol/day, 17.1 11.8
mmollday) than in the 5 normal control subjects with acid loading (92.0
27.6 mmol/day) (P < 0.01). (4) Twenty-four hour phosphorus and
titratable acid excretion were decreased in both patients with high serum
anion gap and patients with normal anion gap (269 189 mg/day, 7.5
3.9 mmol/day vs. 300 216 mg/day, 5.5 4.4 mmol/day) than in those of
normal control subject with acid loading (840 152 mg/day, 35.2 12.7
mmol/day) (P < 0.01). (5) Fractional excretion of phosphorus had a
positive relation with fractional excretion of anions in the 13 CRF patients
with increased serum anion gap (r = 0.59, P < 0.05). We concluded that
metabolic acidosis of CRF could be a high anion gap type with decline of
the renal function. Further studies about the roles of organic anions
including phosphates in CRF will be required.
Distribution of serum potassium concentration and analysis of associ-
ated factors with hyperkalemia in chronic hemodialysis patients. H.J.
Kim, S.H. Hwan& C.H. Par/c C.M. Kang, and H.C. Park; Department of
Internal Medicine, Hanyang University College of Medicine, Seou1 Korea.
The predialysis routine serum potassium concentration and possible
associated conditions with abnormal potassium concentration were ana-
lyzed in 86 patients on chronic maintenance hemodialysis. Mean potas-
sium concentration (±sD) was 5.2 0.6 mEq/liter (range 3.8—6.7 mEq/
liter). Normokalemia was found in 65 of 86 patients (76%), whereas
hyperkalemia was shown in 21 of 86 (24%). No one on chronic hemodi-
alysis had hypokalemia. Two of 4 diabetic patients had hyperkalemia. Two
subdivided groups with and without hyperkalemic drugs (ACE inhibitors
and/or beta blockades) didn't show any significant difference (5.2 0.6 vs.
5.2 0.7 mEq/liter), and 2 groups divided by kinds of dialysate had similar
findings (acetate vs. bicarbonate 5.2 0.6 vs. 5.2 0.7 mEq/liter).
Significant differences between predialysis normokalemic and hyperkale-
mic patients were found in BUN (77 14 vs. 87 15 mg/dl, P < 0.01),
total CO2 (17.6 1.6 vs. 16.6 2.1 mEq/liter, P < 0.05), and anion gap
(17 2.4 vs. 18 2.0 mEq/liter, P < 0.01), whereas no significant
differences in weight gain over dry weight, serum phosphate and creatinine
concentration, and serum albumin level were noted. In this study we
observed a small but substantial population of hyperkalemic patients
(24%) on chronic hemodialysis. Besides well-known dietary indiseretions,
metabolic acidosis, underlying diseases for chronic renal failure, and other
possible associated factors require further consideration in such cases.
Synergistic effect of sodium bicarbonate and insulin in glucose in the
therapy of hyperkalemia accompanied by metabolic acidosis. H.J. Kim,
I. W. Sohn, C.H. Park; Y.H. Ahn, C.M. Kang, and H. C. Park; Department of
Internal Medicine, Hanyang University College of Medicine, Seou1 Korea.
Hyperkalemia, as well as resistance to insulin, were considered to be some
of the metabolic derangements caused by metabolic acidosis. Therefore,
we studied the efficacy of the degree of correction in hyperkalemia by the
concomitant administration of sodium bicarbonate and insulin in glucose
in 6 hyperkalemic patients with metabolic acidosis on hemodialysis and
compared with those of other conventional therapeutic approaches for
hyperkalemia after 60 minutes in each regimen. Sodium bicarbonate
infusion (8.4%, 2 mEq/min) alone induced a significant rise in blood
bicarbonate and pH, but failed to the lower serum potassium level (6.4
0.1 vs. 6.3 0.2 mEq/liter, before and after). However, insulin in glucose
(5 mU/kg/mm) intravenously administered, significantly lowered serum
potassium from 6.3 0.1 to 5.7 0.1 mEq/liter (P < 0.005), and
furthermore, the concomitant administration of sodium bicarbonate and
insulin in glucose showed the most prominent decline from 6.2 0.2 to 5.2
0.1 mEq/liter (P < 0.005) with similar but lesser increases in blood
bicarbonate and pH compared with those of sodium bicarbonate admin-
istration alone. Also, the degree of change of potassium value following it
revealed the most rapid decline (—1.2 0.1 mEqfliter), even greater than
that of dialysis (—1.0 0.1 mEq/liter). Basal plasma insulin levels before
sodium bicarbonate alone, insulin in glucose alone, and sodium bicarbon-
ate in combination with insulin in glucose were similar but, as expected,
significant marked increments of insulin levels from basal levels after
infusion of insulin in glucose with or without sodium bicarbonate followed.
However, there was no significant difference in insulin level between
insulin in glucose alone and sodium bicarbonate with insulin in glucose
(196 18.0 vs. 201 26.4 jiU/ml). Plasma epinephrine and norepineph-
rifle values before and after these three kinds of treatment didn't show any
significant differences. It is concluded that in hyperkalemic emergencies
accompanied by metabolic acidosis, as in terminal renal failure patients,
concomitant administration of sodium bicarbonate and insulin in glucose
is a fast and effective method of therapy, due to their synergistic effect,
suggestive of overcoming insulin resistance partly related to metabolic
acidosis.
Development of an ESRD registry program using HITEL® Closed User
Group program. D.C. Han, LU. An, MC. Kim, H.T. Kim, MK Cha, MS.
Park; S.D. Hwang and H.B. Lee, Hyonam Kidney Laboratory and Depart-
ment of Preventive Medicine, Soon Chun Hyang University and Korea PC
Telecom, Seou4 Korea. The Korean ESRD Registry has to date relied
upon written questionnaires distributed and collected from individual
dialysis and transplantation centers by mail. This method is time consum-
ing and demands repetitive work by all parties concerned, Personal
computer (PC)-based direct communications between centers are efficient
but more expensive. Recently, a communication program such as Hitel®
Closed User Group (CUG) has been developed by Korea PC Telecom Co.
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Ltd., and this program allows easy access and management of specific
information. The advantages of using Hitel® CUG program are: (1) Easy
access from any center 24 hours a day. (2) Fast transfer of data between
centers without the need for mailing questionnaires. (3) Easy to compile
database information of all ESRD patients. (4) Less expensive than
PC-based direct communications between centers. (5) Nationwide organ
sharing program for organ transplantation can be easily incorporated.
Conclusion: We propose that the Korean ESRD Registry utilize the
Hitel® CUG program for data collection and analysis in the future.
Calcium free hemodialysis for the management of hypercalcemia. W.S.
Koo, D.S. Jeon, S.J. Ahn, YS. Kim, YS. Yoon, and B.K Bang, Department
of Internal Medicine, Catholic University Medical College, Seoul, Korea. The
initial treatment for hypercalcemic crisis consists of hydration and main-
tenance of a saline diuresis. With the exception of saline induced diuresis,
most forms of therapy are either ineffective, slow in action, or have major
serious disadvantages, especially in patients with advanced renal failure.
Although hemodialysis is generally mentioned as a potential therapy in
several articles, actual prescription of such an approach has not yet been
properly defined. To establish the guidelines for the use of dialysis and to
determine its optimal prescription for hypercalcemia, a prospective study
on calcium free hemodialysis was performed in 6 hypercalcemic patients
(mean age 57 years, range 42—65) with renal failure not responding to
forced saline diuresis. The causes of their hypercalcemia were multiple
myeloma (N = 3), lung cancer (N = 2), and renal cell carcinoma (N = 1).
Cuprophan hollow-fiber dialyzers with a surface area of 0.8 m2 (CS-108G,
COBE laboratories, Inc.) were used for all treatments. Calcium free
dialysate contained (in mmol/Iiter): sodium 135, potassium 2.5, chloride
108, magnesium 0.75, and bicarbonate 30. Each patient was dialyzed at the
same blood flow rate (250 mI/mm) and dialysate flow rate (500 mI/mm)
throughout the study. The plasma calcium concentrations fell from a mean
value of 2.92 0.21 mmollliter (range 2.55—3.25) to 2.58 0.16 mmol/liter
at 1 hour of hemodialysis and to 2.16 0.33mmol/liter (range 1.63—2.53)
following 2—3 hours of hemodialysis. Mean hemodialysis time was 154
30 minutes and mean Kt/V urea was 0.72 0.19. The ionized calcium (N
= 4) decreased from 1.44 0.14 mmollliter to 1.07 0.13 mmol/liter. No
patient showed any hypocalcemic symptoms and signs during hemodialy-
sis. There was a significant positive correlation between the decrease in the
plasma calcium concentration and the Kt/V urea (y = 1.47x — 0.3; r =
0.96, P < 0.001). This rate of decrease in plasma calcium concentration did
not appear to produce adverse effects in all patients. We conclude that
calcium free hemodialysis is indicated when the presence of severe renal
failure prevents the administration of large volumes of intravenous fluids
to hypercalcemic patients. The amount of dialysis (Kt/V urea) can be used
to predict the decrease in plasma calcium concentration during calcium
free hemodialysis.
Effect of desferrioxamine on plasma endothelin concentration in main-
tenance hemodialysis patients. G.B. Choi H.K Jung, S.A. Lim, WB. Pyun,
D.H. Kang, and KI. Yoon, Department of Internal Medicine, Ewha Woman's
University Medical Center, Seoul, Korea. Membrane bioincompatibility can
induce acute life-threatening reactions or chronic changes which may
interfere with the immune response, impact upon the patient's nutritional
status, and cause residual renal function to deteriorate. One of the
biologic effects attributable to membrane bioincompatibility is comple-
ment activation. Particularly, C5a can stimulate neutrophils to release
oxygen free radicals, resulting in endothelial cell injury. However, desfer-
rioxamine (DFO) acts as an iron chelator, which blocks the iron catalyzed
Haber-Weiss reaction and inhibits release of oxygen free radicals from
activated neutrophils. Endothelin (ET), which has mitogenic and vasocon-
strictive properties, can be released from endothelial cells in response to
vascular damage, such as atherosclerosis. Therefore, we examined the
relationship between membrane bioincompatibility and plasma ET con-
centration. During the last 1—2 hours of hemodialysis, DFO (40 mg/kg in
5% D/W 200 cc) was infused intravenously into 13 patients (DFO group),
and placebo (5% D/W 200 cc only) was infused in same manner into 9
patients (control group). We sampled blood for measurement of plasma
ET concentration just before the initiation of hemodialysis on the day of
infusion, on the 2nd—3rd day and on the 7th day after infusion. There was
no statistical difference between the two groups in plasma ET concentra-
tion measured before infusion (5.56 3.50 pg/mI in DFO group, 4.38
2.40pg/mI in control group). In the DFO group, plasma ET concentration
decreased significantly on the 2nd—3rd day (3.49 2.08 pg/mI, P < 0.01),
but increased significantly on the 7th day (5.62 2.95pg/mI, P < 0.05). In
contrast, there were no significant changes in plasma ET concentration in
the control group. There was no significant difference in the decrement of
plasma ET between the cases of transferrin saturation below and above
60%, and there was no relationship between the plasma ET decrement
and transferrin saturation or serum ferritin in the DFO group. In
conclusion, the decrease of plasma ET concentration after DFO infusion
might be the result of diminished endothelial cell injury from oxygen free
radicals. Therefore, plasma ET concentration can be used as an index of
membrane bioincompatibility.
Endotoxin concentration in dialysate. S.K Kang J.J. Nam, KM. Hwang,
and S.K Par/c, Department of Internal Medicine, Chonbuk National Univer-
sity Medical School, Chonju, Chonbu/ç, Korea. Bacterial cells produce a cell
wall, and the cell wall component common to all bacteria is peptidoglycan.
Gram-negative bacteria contain an extra layer in the cell wall structure
called the outer membrane, which is outside the peptidoglycan layer.
Endotoxin (ET) is a component of the outer membrane of gram-negative
bacteria and is a lipopolysaccharide which has been known to contribute
to various biological activities, such as pyrogenicity, shock, and depression
of blood sugar. Because preventing pyrogen from contaminating in the
parental drug is extremely important in clinical medicine, the pyrogen test
is imposed on quality control of these drugs and routinely performed in
the pharmaceutical industries. To determine the source of ET contami-
nation in our water processing and dialysate system, endotoxin levels
during hemodialysis were measured in municipal tap water, dialysate, and
reverse osmosis system. ET concentration in tap water at the inlet of water
softening is relatively high (85.9 37.1 ng/ml) in Korea, but ET in the
dialysate at the inlet of the dialyzer has not been high, because the water
is purified by reverse osmosis.
Adsorption of j32.microglobulin by hemodialysis membranes. J.H. Ahn,
J.K Park; T W. Lee, C.G. Ihm, and MJ. Kim, Division of Nephrology, Dept.
of Internal Medicine, Kyung Hee University Hospital, Seoul, Korea. Adsorp-
tion is one type of interaction between biomaterials and blood protein. In
the present study we investigated whether 132-microglobulin might be
adsorbed by cuprophan (CUP), cellulose acetate (CA), polymethyl-
methaciylate (PMMA) and polyaciylonitrile (PAN) membranes. Periph-
eral blood mononuclear cells were cultured on hollow fiber materials
made from each hemodialyzer. /32-microglobulin concentrations in the
supernatant were measured at 3 and 6 days of culture, respectively. Each
hollow fiber material (5 mg, 15 mg, 30 mg and 45 mg) was incubated with
the uremic serum. p2-microglobulmn concentrations were measured in the
serum at 1 and 24 hours of incubation. After 3 and 6 days of culture,
132-microglobulin concentrations in the supernatant with PAN, CUP and
CA membranes were significantly lower than that in the supernatant
without membrane. After 1 hour incubation, the 132-microglobulin con-
centrations in serum with PAN (15 mg, 30 mg, and 45 mg) were 474.1
455.3 ng/ml, 455.3 6.9 ng/ml and 390.9 4.4 nglml, all significantly
lower than that in serum without membrane (563.2 20.3 ng/ml) (P <
0.05). After 24 hours incubation, J32-microglobulmn concentrations in
serum with PAN 15 mg, 30 mg and 45 mg were 455.4 5.6 ng/ml, 360.0
14.0 nglml and 287.2 5.9 ng/ml, all also significantly lower than that
in supernatant without membrane (601.0 19.6 ng/ml) (P < 0.05). In
conclusion, PAN membrane has a significant capacity to adsorb J2-
microglobulin. Whether this efficient adsorption of f32-microglobulin in
vitro by PAN membrane might be beneficial to prevent dialysis-related
amyloidosis in hemodialysis patients remains to be defined.
Comparison of peripheral vein method and low blood flow method for
measurement of vascular access recirculation. C. W. Yang, S.H. Lee, YS.
Kim, S.f. Ahh, Y.S. Chang, YS. Yoon, and B.K Bang Department of
Internal Medicine, Catholic University Medical College, Seoul, Korea. The
measurement of dialysis access recirculation has important diagnostic
implications. There is recent recognition that its traditional means of
measurement are fraught with the potential for substantially overestimat-
ing access recirculation. Most of the potential error in the measurement
can be overcome by using an arterial rather than a venous specimen for
the systemic sample. Therefore, we performed this study to compare the
low-flow arterial (LFA) technique to the standard (ST) method in 51
patients undergoing hemodialysis. The ST method was performed simul-
taneously with the LFA recirculation technique. Mean blood flow was 246
ml/min and mean venous pressure was 107 mm Hg. The results were as
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follows: (1) Recirculation by ST and LFA method was 22.9% and 15.2%,
respectively (P < 0.01), and mean difference of recirculation between the
two methods was 7.7% (range 1%—25%). (2) Recirculation by LFA
method was well correlated with the ST method (r = 0.87,P = 0.0001). (3)
Difference of recirculation between ST and LFA method was: fistula type
(native; 8.2%, graft; 7.0%, P > 0.05); venous pressure [high VP (> 150
mm Hg); 8.9%, low VP; 7.6%, F> 0.05]; hemoconcentration (Hct> 30;
10.2%, Hct < 30; 8.2%, P > 0.05); and fistula site (forearm; 7.6%,
fernoral; 9.4%, P > 0.05). In conclusion, the LFA method was well
correlated with the ST method, and fistula type, venous pressure, hemat-
ocrit level and fistula site did not affect the difference of recirculation
between the two methods. It was suggested that the LFA method can be
used as alternative to the ST method for measuring recirculation in
patients undergoing hemodialysis.
Prevalence and mode of transmission of hepatitis C virus infection.
S.H. Lee, Y.S. Kim, S.A. Yoon, C.W. Yang S.K Yoon, D.C. Jin, S.f. Ahn,
WS. Koo, KS. Shim, Y.S. Yoon, B.K Bang, and B.S. Kim, Dept. of Internal
Medicine, Catholic University Medical College, Seou4 Korea. To investigate
the prevalence and mode of transmission of hepatitis C virus infection in
hemodialysis (HD) patients, 286 HD patients in the Catholic Medical
Center were screened for anti-HCV antibodies (Ab) by 2nd generation
RIA, between April 1992 and March 1994. In 1993, anti-HCV Ab and
HCV RNA (PCR with 5' non-coding region primers) were tested in 144
patients. Genotypes were determined by double nested PCR with group
specific primers from the NS5 region in HCV RNA positive patients.
Males were predominant (157 vs. 129), the mean age was 37 years (17—79
years), and the mean duration of HD was 37 months (1—140 months).
Prevalence of anti-HCV Ab was 30.3% (76/251) in 1993 and 20.4%
(32/157) in 1994. Of the 139 patients tested annually, positive seroconver-
sion was 11.2% (11/98). Eleven seroconverted patients had a significantly
longer duration of HD (mean 52, 6—97 months) than 86 non-serocon-
verted patients (mean 13, 1—88 months) (P < 0.0001), and tended to get
more transfusions (3.7 4.7 U vs. 1.8 3.3 U, P = 0.09). Of the 11
seroconverted patients, 5 (45%) had no histoiy of transfusion. Simulta-
neous tests resulted in 13.9% (20/144) positivity by anti-HCV Ab and
16.0% positivity by HCV RNA (23/144). Relative percentages of geno-
types were Ki (52%), K2 (43.4%), and undetermined (4.3%). In conclu-
sion, the prevalence of anti-HCV Ab was 20 —30%, positive seroconversion
was 11.2%, and the surrounding environment (including the HD ma-
chine), as well as transfusion, may participate in the transmission of
hepatitis C virus infection.
Factors contributing to morbidity and mortality in chronic hemodial-
ysis patients. IS. Lim, G.H. Kim, R. W Chun, D. W. Chae, YC. Lee, and
J. W. Noe, Department of Internal Medicine, Medical College, Hallym
University, Seoul, Korea. Several factors have been raised as contributing to
morbidity and mortality among patients with end-stage renal disease
treated with hemodialysis. In order to evaluate morbidity and mortality,
and the factors contributing to them in chronic hemodialysis patients, we
analyzed retrospectively the demographic characteristics, regularly tested
laboratory findings (CBC, blood chemistry, chest X-ray, ECG), hospital-
ization rate, and gross mortality among 84 patients in the Hallym
University Medical Center from February 1, 1992 to January 31, 1994.
Mean age of the patients was 54.3 years (range 23—79 years); 41 were men,
43 were women, and 30 (35.7%) had diabetes. The mean duration of
hemodialysis was 33.1 months (range 3—125 months). Forty-four patients
(52.4%) required hospitalization during the 2-year follow-up period, and
the causes of hospitalization were infection, congestive heart failure, and
vascular access problems, in descending order of frequency. A total of 18
(21.4%) of the patients died during the 2-year follow-up period, and
cardiovascular disease was the most common cause of death. Factors such
as advancing age, the duration of hemodialysis, and diabetes, were neither
associated with the risk of hospitalization nor that of death. The mean
serum albumin concentration (± SD) in the dead patients (3.4 0.4 g/dl)
was lower (P < 0.01) than in the surviving patients (3.8 0.4 g/dl).
Compared with patients who had serum albumin concentrations of  3.5
g/dl, patients with serum albumin concentrations below 3.5 g/dl had an
increased (8.14) odds ratio for death. We concluded that a regularly tested
serum albumin concentration was predictive of mortality in chronic
hemodialysis patients.
Serum lipoprotein(a) in diabetic nephropathy. W.H. Lee, J.H. Ahn, T. W.
Lee, C.K Ihm and M.J. Kim, Department of Internal Medicine, School of
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Medicine, Kyung Hee University, Seoul, Korea. Lipoprotein(a) [LP(a)] is a
subspecies of low-density lipoprotein and has been shown to be associated
with the pathogenesis of thrombosis-related disease. It is already known
that patients with diabetic nephropathy usually have vascular complica-
tions such as coronary artery diseases and cerebrovascular accidents. We
investigated LP(a) levels in 82 patients with diabetic nephropathy. They
were divided into four groups according to the levels of urinary albumin
excretion and serum creatinine. Group I (N = 32): urine microalbumin 
13 .sg/min; Group II (N = 23): protein (—) on urinalysis + urine
microalbumin> 13 g/min; Group III (N = 16): urine protein (+) on
urinalysis with serum creatinine level < 2.0 mg/dl; Group IV (N =11):
urine protein (+) on urinalysis with serum creatinine level  2.0 mg/dl.
LP(a) levels were 29.9 4.7 mg/dl in Group I, 43.6 9.1 mg/dl in group
II, 80.6 20.6 mg/dl in group Ill, and 81.6 16.1 mg/dl in group IV
(mean SEM). The level of LP(a) in group IV, group III, and group II was
significantly higher than that of group I (P = 0.007, P = 0.010, P = 0.032,
respectively). No significant correlation was observed between the level of
LP(a) and that of total lipid, total cholesterol, and triglyceride in all
groups. These results indicate that LP(a) concentrations are increased in
the patients with diabetic nephropathy with microalbuminuria or overt
proteinuria. The presence of microalbuminuria may be an important
determinant for the elevated LP(a) level in diabetic nephropathy.
Lipoprotein (a) and ischemic heart disease in patients undergoing
continuous ambulatory peritoneal dialysis (CAPD). D.H. Kang S.W. Lee,
S. W. Kang H.S. Kim, KH. Chot, S.K Ha, H.Y. Lee, and D.S. Han, Dept. of
Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Atherosclerotic vascular disease is a leading cause of morbidity and
mortality in ESRD patients undergoing maintenance dialysis. Although
deranged lipoprotein metabolism is considered as a cardiovascular risk
factor in these patients, it is not clear what abnormality is indeed
atherogenic. Some epidemiologic studies revealed that increased lipopro-
tein (a) [LP(a)] concentration is an independent risk factor for develop-
ment of coronary heart disease. In this study we examined the concentra-
tion of LP(a) of 89 CAPD patients (males:females, 54:35, mean age 43.8
years) in our center and compared the LP(a) level between patients with
and without ischemic heart disease (IHD) to see whether a high LP(a)
level could be a marker of atherogenic risk in CAPD patients. We also
analyzed factors which affect LP(a) concentration with a particular
emphasis on the role of nutritional status and dialysis adequacy. LP(a)
level in our CAPD patients was 44.7 26.4 mg/dl. The mean concentra-
tion of cholesterol and triglyceride was 186.8 mg/dl and 145.6 mg/dl,
respectively. Fourteen patients with IHD had a significantly higher LP(a)
level than those without it (61.5 27.4 vs. 25.5 20.1 mg/dl, P < 0.01).
NPCR and weekly KT/V urea were also decreased in patients in the group
with IHD. There was no significant difference in total cholesterol,
triglyceride, and HDL cholesterol between the patients with and without
IHD. No significant correlation was observed between LP(a) and age,
duration of CAPD, lean body mass, percent body fat, total cholesterol,
triglyceride and albumin. Thirty-two (35.9%) out of 89 patients had LP(a)
concentration above 30 mg/dl. In the high LP(a) patient group, calculated
arm muscle area and total body muscle were decreased with a decreased
concentration of BUN and weekly KT/V urea. In conclusion, a high level
of LP(a) may contribute to an increased risk for ischemic heart disease in
CAJ'D patients, and there may be a relationship between the presence of
ischemic heart disease, the increased LP(a) level and adequacy of dialysis.
Further study is needed to confirm these relationships and to clarify the
effects of intensification of dialysis and lipid lowering agents.
Lp(a) and other lipid profiles in chronic renal failure (CRE) and after
kidney transplantation (KT). S. Cho, J.H. Kim, J.H. Bang, D.H. Kim, J. W.
Lim, EL. Kim, and D.K Cho, Department of Internal Medicine, Kyungpook
University Hospital, Taegu, Korea. Recent studies have shown that uremic
patients with conservative treatment (CT), hemodialysis (HD), peritoneal
dialysis (PD) have greatly increased plasma levels of Lp(a) compared to
healthy controls (HC), while the level of Lp(a) was decreased after KT.
There is, however, a controversy about the significance of increased Lp(a)
levels in CRF. This study was conducted to assess the serum concentration
of Lp(a) and its relationship between various biochemical parameters as
well as vascular complications in 104 patients with CRF (CT:39, HD:34,
PD:31), 23 patients with KT, and 31 with HC. Lp(a) in CRF patients with
CT (41.91 24.66 mg/dl), HD (37.16 18.99 mg/dl) and CAPD (32.68
21.59 mg/dl) was significantly increased (P < 0.001 in 3 groups) compared
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to HC (16.39 8.22 mg/dl), indicating that the types of treatment for CRF(CT, HD or PD) did not have an effect on Lp(a) concentrations. By
contrast, the Lp(a) in KT (17.00 17.06 mgldl) was similar to HC, being
significantly decreased compared to patients with CF, HD and CAPD.
Among 65 HD and CAPD patients, twenty patients (21 episodes) have
suffered from various vascular complications (11 arteriovenous fistula
thrombosis, 6 coronaiy heart disease and 4 cerebrovascular thrombosis).
There was no significant difference between the Lp(a) values in the 20
CRF patients with vascular complications compared to 45 patients without
such complications (34.75 21.84 mg/dl vs. 35.14 19.74 mg/dl). The
other lipid profiles of CRF were characterized by increased triglyceride
(TG) and total cholesterol (TC) in CT, by increased TC in HD, by
increased TG and TC, compared to HC. KT had elevated TG, TC as
compared to HC, and it had elevated HDL cholesterol as compared to
HC, CT, HD. The Lp(a) in CT was correlated with BUN, Sr, and
inversely with serum albumin. The Lp(a) in HD was correlated with Se,.
LDL cholesterol and inversely with HDL cholesterol. The Lp(a) in CAPD
was correlated inversely with the duration of CAPD. And the Lp(a) in KT
was correlated with TG, TC, LDL cholesterol. In summary: (1) The Lp(a)
in CRF patients irrespective of treatment modality (CT, HD and CAPD)
was elevated compared to HC; (2) The concentration of the Lp(a) was
normalized after KT, while other lipid abnormalities persisted, (3) Be-
tween vascular complications and Lp(a) there was no relevant relation-
ship.
Sieving coefficient for small solutes during experimental peritoneal
dialysis in rats. M.S. Par/c, 0. Heimburger, J. Bergstrom, J. Waniewski, A.
We,ynskc, and B. Lindholm, Karolinska Institute, Stockholm, Sweden;
Hyonam Kidney Laboratoiy, Soon Chun Hyang University, Seoul, Korea; and
Polish Academy of Sciences, Warsaw, Poland. A single 4-hour experimental
peritoneal dialysis was performed in 6 normal Sprague-Dawley (SD) rats
to investigate sieving coefficient (S) for small solutes during peritoneal
dialysis. A modified Dianeal 3.86% solution with approximately the same
concentration of urea, sodium and potassium as in the rat plasma,
isochratic solution, was used to avoid diffusion of solutes under investiga-
tion and to achieve sufficient ultrafiltration. As a control, a 4-hour
peritoneal dialysis in 7 normal SD rats was performed using the conven-
tional Dianeal 3.86% solution. S was calculated (1) from the mass and
volume balances for the initial 30 minutes of the exchange (Si, isochratic
method) for the isochratic solution; and (2) by using a membrane model
of mass transport (SM). The value of S and SM for urea, sodium and
potassium with the isochratic solution was similar. For urea and sodium, S
values were within the physiologic range 0—1, whereas S values for glucose
were close to zero and were negative for potassium. SM was greater for
glucose, urea, and sodium with the isochratic solution; however, SM for
potassium was significantly lower than with the isochratic solution. We
conclude that the net sieving coefficient, S1 and 5M' for urea and sodium
were lower than unity in the rats dialyzed with the two solutions and did
not differ from the previously reported S values measured in CAPD
patients with the isochratic solution. However, the transport of potassium
was abnormal with the isochratic solution, suggesting a mechanism of
potassium transport other than passive diffusive and convective transport.
Albumin-based solutions for peritoneal dialysis: Investigations with a
rat model. MS. Park; 0. Heimburger, J. Bergstrom, .1. Waniewski, A.
Weiynsk4 and B. Lindholm, Karolinska Institute, Stockholm, Sweden;
Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, Korea; and
Polish Academy of Sciences, Warsaw, Poland. To evaluate albumin as an
osmotic agent for peritoneal dialysis, the peritoneal fluid and solute
transport were investigated during a 4-hour single cycle peritoneal dialysis
with albumin-based dialysis solutions. Two different albumin solutions
were used in 15 normal Sprague-Dawley rats: isotonic 7.5% albumin
solution (ADS 1, N = 7) and a combined 7.5% albumin and 1.36% glucose
solution (ADS 2, N = 8).A standard 1.36% Dianeal solution was used in
6 control rats. The rate of the intraperitoneal volume change (Q) was
positive during the initial 90 minutes with ADS 2 and during the initial 60
minutes with the Dianeal 1.36% solution, but negative with ADS 1. The
estimated rate of transcapillazy ultrafiltration (Q) was positive with all
three solutions throughout the dialysis. Q with ADS 1 increased gradually
during the initial 90 minutes and then remained stable, whereas it
decreased with ADS 2 and Dianeal 1.36% solution. Q0 with ADS 2 did not
differ from that with Dianeal 1.36% solution during the initial 60 minutes,
but it was significantly higher during the later part of dialysis. The value of
Q,, during the last two hours of dialysis was similar with ADS 1 and ADS
2 and significantly higher than that with Dianeal 1.36% solution (0.05
0.007 mI/mm, P < 0.017). The peritoneal reabsorption rate, Qa, was
similar in all three groups. After 4 hours of dialysis, 21% and 25% of the
initial amount of albumin were absorbed from the peritoneal cavity with
ADS 1 and ADS 2, respectively. We conclude that albumin can be
regarded as a theoretically ideal osmotic agent in peritoneal dialysis to
yield prolonged ultrafiltration and to compensate protein loss during
dialysis with conventional dialysis solution. However, its high cost restricts
its clinical application at present. The results of the present study may be
useful as reference data in the evaluation of other alternative osmotic
agents.
Progression of peritoneal fibrosis in rat with experimental peritonitis.
MK Cha, S.Y. Jin, D.C. Han, M.S. Par/c, S.D. Hwang, and H.B. Lee,
Hyonam Kidney Laborato,y and Departments of Pathology, Soon Chun
Hyang University, Seoul, Korea. Fibrosis is a process of normal wound
healing, as in the repair of skin wounds, and is characterized by an increase
in extracellular matrix. Peritoneal fibrosis during CAPD may be a conse-
quence of repeated peritonitis, high intracellular Ca or advanced
glycosylation end-products. In this study the progression of peritoneal
fibrosis after a single episode of Staphylococcus aureus peritonitis was
investigated by examining the types and distribution of newly formed
collagens within parietal and visceral peritoneum in the experimental rat
model. In the normal rat parietal peritoneum, a single layer of mesothelial
cells was laid on a thin stroma of connective tissue, which consisted of
collagen bundles and elastic tissues. In the visceral peritoneum, a single
layer of mesothelial cells was laid over adipocytes of the mesentery and
intestinal serosa. Both types I and III collagen were expressed and
distributed in both parietal and visceral peritoneum in normal rats. During
Staphylococcus aureus peritonitis, the peritoneal membrane was altered
with marked degeneration of the mesothelium and thickening of subme-
sothelial connective tissue by increased accumulation of both types I and
III collagens. The process began in 4 days after peritonitis and progressed
during the 4 weeks of observation. Whether these structural changes will
be associated with functional alterations remains to be seen in the future
studies.
Nutritional assessment and urea kinetic modeling in continuous am-
bulatory peritoneal dialysis patients (CAPD). D.H. Kang, S. W. Kang, S. W.
Lee, H.S. Kim, YK Par/c, J.H. Lee, KH. Choi, FLY. Lee, and D.S. Han,
Dept. of Internal Medicine, Yonsei University College of Medicine, and Dept.
of Food and Nutrition, Yonsei University College of Human Ecology, Seoul,
Korea. There is a high prevalence of protein energy malnutrition in dialysis
patients, with 18 to 56% of CAPD patients showing anthropometric and
biochemical evidence of malnutrition; protein intake in these patients
correlates inversely with both hospitalization and mortality, with definite
evidence of the relationship between dialysis adequacy and protein intake.
However, there are some debates regarding as to which method accurately
assesses the nutritional status of CAPD patients. The present study was
undertaken to know the nutritional status of 130 CAPD patients in our
center, and to examine the correlation between the nutritional index
assessed by subjective global assessment (SGA) with anthropometric data
and dialysis adequacy based on urea kinetic modeling such as normalized
protein catabolic rate (NPCR), KT/V urea and standardized creatinine
clearance (SCar). The mean age of 130 patients (male:female, 75:55) was
44.5 years, and mean CAPD duration was 29.7 months. According to the
nutritional assessment by SGA, 103 patients (79.3%) were classified as
normal, 25 (19.2%) mildly to moderately malnourished, and 2 (1.5%) as
severely malnourished. In the malnourished group, the mean age of
patients was higher (42.8 vs. 48.5 years, P < 0.05), and the mean CAPD
duration longer (22.6 vs. 38.4 months, P < 0.05). The incidence of
peritonitis was higher in the malnourished group (0.70 vs. 1.54 episodes!
patient/year, P < 0.05). Calculated arm muscle area and total body muscle
were reduced in the malnourished group. Hematocrit and BUN were
decreased in the malnutrition group without a significant difference of
serum albumin concentration. Transferrin was also decreased in the
malnourished group (252.2 32.9vs. 188.3 37.4 mg/dl, P < 0.05). IGF-1
was also decreased in the malnourished group (212.2 142.9 vs. 154.3
187.4 ng/ml), but there was no statistical significance. NPCR was lower in
the malnourished group (0.78 0.18 g/kglday) than in the normal
nutrition group (1.05 0.31 g/kg/day, P < 0.01), while KT!V urea was not
significantly different between the two groups. NPCR showed a significant
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positive correlation with LBM & TBM (r = 0.34, r = 0.36, respectively),
and SCr showed a weak correlation with TBM only (r = 0.26, P < 0.05).
In conclusion, NPCR was an excellent indicator of protein nutritional
status, closely correlating LBM and TBM in CAPD patients, and SC
weakly reflected the body protein stores. Therefore, regular follow-up of
NPCR and SCrwith an adequate adjustment of dialysis prescription and
nutritional education may contribute to improving the nutritional status of
patients.
The effects of recombinant human growth hormone (rhGH) in under-
nourished adult continuous ambulatory peritoneal dialysis (CAPD) pa-
tients. D.H. Kang, S. W. Lee, S. W. Kang, H.S. Kim, KH. Cho4 H. Y. Lee, and
D.S. Han, Dept. of Internal Medicine, Yonsei University College of Medicine,
Seoul, Korea. Protein-calorie malnutrition and decreased lean body mass
are frequently observed in end-stage renal disease (ESRD) patients who
are undergoing maintenance dialysis therapy, and it is generally accepted
that suboptimal nutritional status is associated with increased morbidity
and mortality in these patients. Recombinant human growth hormone
(rhGH) is a potent anabolic hormone, and a few studies have demon-
strated improved nitrogen balance with increased incorporation of nutri-
ents into new tissue following administration of rhGH in patients with
chronic renal failure. However, little information is available about adult
ESRD patients undergoing CAPD. Thus, we decided to undertake this
prospective study to know the effects of supraphysiologic doses of rhGH
(10 IU/m2) given thrice weekly for 12 weeks to adult CAPD patients with
poor nutritional status. Changes of subjective symptoms of patients,
biochemical parameters, anthropometric data, KTIV urea, normalized
protein catabolic rate (NPCR), and standardized creatinine clearance
(SCcr) were studied. After rhGH therapy, 6 patients (60%) reported
improved appetite, and 3 (30%) increased their exercise capacity. BUN
was significantly decreased with rhGH therapy (42.6 10.6 vs. 39.5 10.3
mg/dl, P < 0.05), but there were no significant changes in creatinine,
glucose, calcium, phosphorus and albumin concentration. Percent ideal
body weight and total body muscle increased significantly after rhGH with
a significant reduction of percent body fat. Maximum oxygen consumption
capacity (19.10 5.75 vs. 23.29 3.82 mI/kg/mm, P < 0.01), rate-pressure
product, hand grip strength and back-lift strength were also increased.
NPCR fell from 0.78 0.13 g/kg/day to 0.60 0.15 g/kg/day, but residual
renal function, KT/V urea and SCr revealed no significant changes after
rhGH. GH and insulin-like growth factor-I (IGF-I) concentration rose
significantly after 6 weeks of rhGH with a significant decrease of iPTH
concentration. In a group of patients with the changes of urea nitrogen
appearance above 500 mg after rhGH, pretreatment BUN, albumin and
transferrin concentration were significantly higher. No significant delete-
rious side effects were observed, except for minor side effects, such as 2
cases of facial edema and 1 case of pruritus. In summary, rhGH in
undernourished adult CAPD patients improved the subjective symptoms
with the decreased protein catabolic rate and increased body muscle.
Follow-up study about the long-term effects of rhGH and whether these
anabolic effects will be maintained after discontinuation of rhGH is
necessary to further define the potential clinical utility of rhGH in adult
ESRD patients.
Nutritional comparison between hemodialysis and continuous ambula-
tory peritoneal dialysis: A single-center experience in Korea. Assessment
of nutrition with anthropometry and infrared interactance. S.H. Kim, M.J.
Kim, V.1. Kim, and K W. Lee, Department of Internal Medicine, Inha
University Hospita4 Sungnam, Korea. The assessment of nutrition is an
essential component in the total care of the end-stage renal disease
(ESRD) patient. In a cross-sectional study examining nutritional status, 46
patients on hemodialysis (FID) and 30 patients on continuous ambulatory
peritoneal dialysis (CAPD) were evaluated. The assessment included
anthropometric measures (height, weight, triceps skin-fold thickness,
mid-arm circumference), infrared interactance for body composition
(body fat, lean body mass) by Futrex 5000R, and biochemical measures
(serum albumin, blood urea nitrogen, creatinine, total cholesterol). There
were no statistically significant differences in mean age, height and body
weight between the 2 groups. There were significant differences in the
mean TSF (12.9 0.8 mm vs. 15.3 1.29 mm) and MAMC (19.8 0.3
cm vs. 21.0 0.5 cm) values between the two groups. The mean of MAC
(23.9 0.4 cm vs. 25.8 0.4 cm) and body fat (20.1 0.9% vs. 24.4
1.3%) in infrared interactance was higher in CAPD patients than in HD
patients. No significant differences were found between the two groups in
the lean body mass (44.4 1.0 kg vs. 43.7 1.3 kg) in infrared
interactance. The mean serum BUN (77.1 3.0 mg/dl vs. 43.4 2.1
mg/dl), creatinine (12.2 0.5 mg/dl vs. 9.4 0.6 mg/dl), and albumin (3.73
0.06 g/dl vs. 3.49 0.09 g/dl) was significantly higher in the HD patients
than in the CAPD patients. The mean of total cholesterol (135.7 4.9
mg/dl vs. 188.6 6.2 mgldl) was significantly increased in CAPD patients.
We observed a poorer calorie nutritional status in HD patients than in
CAPD patients.
Variant manifestations of tuberculosis in a dialysis unit: A single.
center experience in Korea. V.1. Kim, MJ. Kim, S.H Kim, and KS. Song,
Department of Internal Medicine, Inha University Hospital, Sungnam, Korea.
Impaired host defense mechanisms have been cited as contributing factors
for the increased susceptibility to infections in patients undergoing
maintenance dialysis. It is suspected that tuberculosis occurs with greater
frequency among chronic renal failure patients than in the general
population. In Korea, there was no literature to estimate the prevalence of
tuberculosis in patients on maintenance dialysis. Therefore, we analyzed
and reviewed the incidence of tuberculosis, its clinical features, treatment
and prognosis of the hemodialysis and continuous ambulatory peritoneal
dialysis patients in our dialysis unit after August 1985. Tuberculosis was
diagnosed in a total 13 of 130 hemodialysis and 79 continuous ambulatory
peritoneal dialysis patients, with an incidence of 6.2%: 6 of the patients
were males, 7 were females, and there was no statistical difference in the
sex ratio. The average period was 24.2 months from the start of mainte-
nance dialysis to developing tuberculosis (5—58 months). These cases
consisted of: 2 miliary tuberculosis, 6 tuberculous peritonitis, 4 tubercu-
bus lymphadenitis, and 1 pulmonary tuberculosis. There was a much
higher incidence of extrapulmonary tuberculosis in 10 Out of 13 patients
(76.9%), and the major symptoms were fever of unknown origin, chill,
general weakness, weight loss, abdominal pain. The patients were admin-
istered isoniazid, rifampin, and pyrazinamide for 6 months. Seven patients
were cured (53.8%), 3 died during the therapy, and 3 are still using the
antituberculous medications.
Serum soluble HLA class I antigen levels in patients undergoing
hemodialysis and renal transplant recipients: C. W. Yang, D.C. Jin, S.J.
Ahn, TK Kim, YS. Kim, H. Han, YS. Chang, and B.K Bang, Department
of Internal Medicine, Department of Microbiology, Catholic University
Medical College, Seoul, Korea. It has been suggested that soluble human
histocompatibility leukocyte antigen class I (S-HLA-I) plays an important
role in the immune recognition of antigens. However, function and
biologic significance of S-HLA-I in uremic state and renal transplantation
is unclear. Therefore, we performed this study about whether S-HLA-I
represents immunologic status in uremic patients, and whether this
molecule might be used as a useful parameter of graft pathology and
function in renal transplant recipients. Study populations were the pa-
tients undergoing hemodialysis (N = 61) and renal transplant recipients(N = 21). Measurement of S-HLA-I was made by sandwich ELISA. The
results were as follows: S-HIA-I levels in patients undergoing hemodial-
ysis (N = 61) were not significantly different compared to normal controls[N = 92, 429.2 391.1 ng/ml (range: 50—1560 ng/ml) vs. 415.6 256,1
ng/ml (range: 50—1220 ng/ml), P < 0.05]. Sex, age, duration of dialysis and
dialysis procedure did not affect S-HLA-I levels. After renal transplanta-
tion, S-HLA-I levels decreased significantly (574.8 431.1 ng/ml vs. 226.7
202.8 ng/ml, P = 0.0001), but this was not correlated with the serum
creatinine level (r = 0.16, P> 0.05). In the acute rejection episode (N =
8), S-HLA-I levels increased significantly compared to the prerejection
period (642.8 296.1 ng/ml vs. 305.5 194.7 ng/ml, P = 0.0002). In
conclusion, S-HLA-I may be used as a parameter of monitoring graft
rejection in renal transplant recipients, but the biological significance of
S-HLA-I needs to be investigated further.
Effect of hemoperfusion on treatment for paraquat intoxication. KY.
Lee and T.H. Lee, Nephrology Division, Department of Internal Medicine,
Presbyterian Medical Center, Chonju, Korea. Paraquat is a very potent
herbicide which causes fatal toxicity when ingested, and there is no specific
antidote against it. So it is known that most of the patients who ingested
it die of pulmonary fibrosis. We used hemoperfusion (HP) for the
treatment against paraquat poisoning from July 1993 till March 1994 and
analyzed the data using SPSS/PC ver.4.0 for chi-square and t-test for mean
SD. The results were as follows: (1) A total of 36 paraquat poisoning
patients (22 males and 14 females, mean age 48.8 years) visited our
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hospital, and 18 patients out of 36 received hemoperfusion (total 90
cycles); there were statistically significant differences in ages (41.4 15.6
year vs. 56.2 15.0 year, P < 0.05), but there was no significant difference
in the amount of paraquat ingested (59.9 72.7 ml vs. 78.6 83.6 ml, P
> 0.05), gastric lavages (13/18 vs. 16/18, P > 0.05), and use of Fuller's
earth (8/18 vs. 4/18, P> 0.05) between the patients who received HP and
those who did not receive HP. (2) All the patients who did not receive HP
died, but 9 patients out of 18 who received HP survived (P < 0.005). There
was no significant difference in ages (46.8 9.8 year vs. 36.0 18.8 year,
P < 0.05), amount of paraquat ingested (87.5 94.2 ml vs. 34.8 36.4 ml,
P> 0.05), gastric lavages (7/9 vs. 6/9, P < 0.05), use of Fuller's earth (5/9
vs. 3/9, P> 0.05), and interval from the ingestion of paraquat to HP (52.4
49.9 hr vs. 38.3 39.7 hr, P > 0.05) between patients who died and
those who survived, but Scr levels on arrival in expired patients were
higher than those in surviving patients (5.0 3.5 mg/dl vs. 1.4 0.6 mg/dl,
P < 0.05). Therefore, this suggests that HP is very effective in the
treatment of paraquat poisoning, and HP is the most important factor in
the prognosis of the patients.
Living donor kidney transplantation—A single center experience. J.M.
Kong, J.H. Jung, J.K Kang, I.K Sung, and B.C. Kim, Depts. of Internal
Medicine, General Su,geiy, Urology and Pathology, Maryknoll Hospital,
Pusan, Korea. One hundred cases of living donor kidney transplantation,
carried out between August 1990 and February, 1993 were reviewed. All
were primary transplants. Of these, 30 were living related and 70 were
living unrelated transplants. The numbers of 2, 1 and 0 haplotype matched
recipients of the related were 2, 25 and 3, respectively. The number of
ABDR mismatches of the unrelated (3.7 0.6. 4) was diabetic. Donor
specific transfusion (DST), consisting of 3 stored whole blood transfusions
at 1 week intervals with cyclosporin coverage, were done in 27 related and
73 unrelated candidates. None of the related and 3 of the 73 unrelated
(4.1%) developed sensitization after DST (overall rate 3%). Sixty-two
episodes of acute rejection occurred in 50 recipients, and all of them were
reversed by 1 or 2 cycles of steroid pulses. Both the patient and graft
survivals at 1 year were 100%. To date no patient or graft was lost. We
think that the DST played a role in the outstanding graft survival of our
patients. Considering the very low sensitization rate, DST should be
recommended in living donor kidney transplantation.
Glomerular filtration rate of the allograft kidney before and after
transplantation. H.H. Jung, J.Y. Kang, S.B. Kim, S. Par/c, D.H. Moon, D.J.
Han, J.S. Par/c, and CD. Hong, Departments of Internal Medicine, Nuclear
Medicine, and General Surgery, University of U/san, Seoul, Korea. The
magnitude of the GFR in the transplanted kidney has been studied in
humans, which has been reported to be around 50 to 70% of the donor
total GFR before nephrectomy. These studies, however, did not directly
measure the GFR of the transplanted kidney before nephrectomy and
were estimated on the assumption that each kidney contributed 50% of
the total GFR. We measured GFR using 51Cr-EDTA clearance
(CEDTA), creatinine clearance (Ccr) and estimated creatinine clearance
(ECcr) using the Cockroft-Gault formula in 65 donors of living related
renal transplantation performed in Asan Medical Center from December
1992 to December 1993. With the relative kidney function measured by
DMSA scan, we calculated the GFR of individual kidneys before nephrec-
tomy (DCEDTA, DCr and DECCr, respectively). When renal function
was stable, usually 3 months after transplantation, we repeated CEDTA,
Ccr and ECU. (RCEDTA, RCcr and RECCr, respectively) in 57 recipients.
Eight recipients were excluded because they did not maintain good, stable
renal function within 2 months. These 2 measurements were compared.
Cyclosporin, prednisone, and azathioprine were used as immunosuppres-
sive agents. The relative renal function of donated kidneys ranged from
32.5% to 56.0% (mean 48.5%). As expected there was a close correlation
between RCEDTA and DCEDTA with RCEDTA = 0.64 X DCEDTA +
29.5 mI/mm (r = 0.55, P < 0.01) and the geometric mean of RCEDTAJ
DCEDTA was 116.1% (N = 43). There was also close correlation between
RCcr and DCC. with RCr = 0.44 x DCcr + 47.7 ml/min (r = 0.42, P <
0.01) and the mean of RCcr/DCcr was 146.9% (N = 39). There was a
significant correlation between RECCr and DECCr with RECCr = 0.42 x
DECcr + 45.2 mI/mm (r = 0.40, P < 0.01) and the mean of RECCr/DECCr
was 138.6% (N = 57). Allograft kidneys function at 15 to 45% above the
pre-nephrectomy level, 3 months after the transplantation. This, of course,
assumes that the DMSA scan provides accurate relative function of the
two kidneys in donors.
The effects of cyclosporine A (CsA) on vascular reactivity. H.S. Kim,
S. W. Kang, KH. Choi, H.Y. Lee, D.S. Han, YH. Lee, and B.S. Kang, Dept.
of Nephrology, Ajou University School of Medicine, Depts. of Internal
Medicine and Physiology, Yonsei University College of Medicine, Seoul,
Korea. The recently introduced CsA, a fungal endecapeptide, is frequently
used after organ transplantation and in certain autoimmune diseases due
to its selective inhibition of T cell related immune responses. Despite this
advantage, serious side effects such as nephrotoxicity and hypertension
have limited its use. However, the exact pathophysiological mechanisms of
these complications remain unclear. This study was planned to ascertain
the effect of CsA on vascular reactivity and also its mechanism of action.
By using the thoracic aortic segment of CsA-treated rats, after contracting
the aortic segment with norepinephrine, endothelium-dependent relax-
ation by acetylcholine was compared with the control group which was
treated with cremophor, the vehicle of CsA. The effect of indomethacin,
superoxide dismutase, and L-arginine on the altered endothelium-depen-
dent relaxation of the CsA-treated rat was also evaluated by preincubating
each drug and observing differences in vascular relaxation by acetylcho-
line. Endothelium-independent relaxation by sodium nitroprusside and
the vascular contractility by norepinephrine were compared between
CsA-treated and control groups. Morphological changes in the endothelial
cells and the smooth muscle were also evaluated by light and electron
microscope after the CsA treatment. The results are as follows: the
endothelium-dependent relaxation by acetyicholine was decreased signif-
icantly in the CsA-treated group compared with the cremophor-treated
group. Suppression of endothelium-dependent relaxation in the CsA-
treated group was not reversed after the preincubation with indomethacin
and superoxide dismutase. Suppressed endothelium-dependent relaxation
observed in the CsA-treated group was recovered following premncubation
with L-arginine, the substrate of NO. The endothelium independent
relaxation by nitroprusside was also decreased in the CsA-treated group
compared with the cremophor-treated group. No significant changes in
vascular contractility by norepinephrine were noted in the CsA-treated
group. Morphological changes after the CsA treatment were mainly
observed in the vascular endothelial cells: cuboidal changes of the
endothelial cells in the renal artery and appearance of cytoplasmic
vacuoles and phagolysosome within the endothelial cells, and detachment
of the endothelial cells from the basement membrane in the aorta. From
the above results, it can be concluded that the main effect of CsA on the
vascular reactivity is inhibition of endothelium-dependent relaxation and
its principal mechanism of action seems to be the defect in the NO
forming mechanism from the L-arginine caused by CsA rather than the
increased activity of the EDCF such as prostaglandin H2, thromboxane A2,
or superoxide anion.
Increase in the ratio of urinary throinboxane B2(TxB2) to PGF1, and
decrease in PGF1, in renal transplant recipients treated with cyclosporin.
J.Y Lee, M.K Kim, S.D. Sung, D.S. Kang, and J.M. Kong, Department of
Internal Medicine, Maiyknoll Hospital, Pusan, Korea. One of the mecha-
nisms of the cyclospormn-induced renal vasoconstriction is the alteration of
the prostaglandin (PG) metabolism. To investigate the change of PG
production and renal hemodynamics in renal transplant recipients and to
determine the effect of cicletanin [a prostacyclin (PGI2) synthetase
stimulator] on PG metabolism and renal hemodynamics, 24 hour urinary
excretion of PGF1 and TxB2, plasma renin activity, plasma aldosterone
and the renal clearances of inulin (CIN) and PAH(CPAH) were determined
at 1 and 4 weeks post-transplantation in 9 renal recipients treated with
cyclosporin, who did not develop acute rejection or urologic complications
during the study period. During the first post-transplant week calcium
antagonist was given to all patients, and between the 2nd and 4th weeks
cicletanin was given to 4 of 9, and calcium antagonist to the rest.
PGF1,, TxB2 CIN CPAH
ng/day ng/day TxB2/PGF1, rn//mm rn//mm
1 week 396 178' 1111 747 2.7 1.2c 39 12 397 89
post-Tx
4 weeks 357 148" 850 704 2.2 0.8' 46 23 329 147
post-Tx
Normal 655 187 745 342 1.1 0.3
mean SD. 'P = 0.067, "P < 0.05, cp < 0.01 vs. normal, "P < 0.083
vs. 1 week post-Tx
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The ratio of urinary TxB2/PGF1 was significantly higher and urinary
PGF1 was lower than normal controls at both 1 and 4 weeks post-
transplant. CIN and appeared to be low both at 1 and 4 weeks.
PGF1,, tended to decrease between 1 and 4 weeks. TxB2, TxB2/PGF1,,, CIN
and CPAH showed no significant change between 1 and 4 weeks. No
significant difference was observed in urinary eicosanoids and renal
hemodynamics at 4 weeks between patients treated with cicletanin and
calcium antagonist. These results indicate that in renal transplant patients
treated with cyclosporin, the ratio of TxB2/PGF1 was increased, primarily
due to the decrease in PGF1,,. Cicletanin was not beneficial in increasing
PGI2 compared with calcium antagonist.
The clinical outcome of HBsAg and anti-HCV positive renal allograft
recipients. H.Y Song, S. W. Kong, KH. Choi, S.K Ha, H.Y. Lee, D.S. Han,
C.K Oh, Y.S. Kim, and K Par/c Dept. of Internal Medicine and Dept. of
Transplant Surgery, Yonsei University College of Medicine, Seoul, Korea.
End-stage renal disease (ESRD) patients receiving dialysis are known to
have a higher prevalence of hepatitis B and C, and although controversy
remains, they are generally known to have a higher rate of hepatic failure,
allograft rejection, infection, and mortality after renal transplantation,
particularly in those patients with significant liver disease such as chronic
active hepatitis or liver cirrhosis. However, little information is available
on the clinical outcome in those antigen positive patients with chronic
persistent hepatitis (CPH) or carrier state. We evaluated the clinical
outcome including hepatic dysfunction, allograft rejection, infection, and
mortality after renal transplantation in 25 patients with positive HBsAg
and/or anti-HCV in whom pre-transplantation peritoneoscopic liver bi-
opsy revealed CPH or carrier state (Group 1), and compared it to that of
28 age- and sex-matched patients who were negative for viral markers
(Group 2). The mean duration of follow-up was 26.8 16.0 months in
group 1 and 21.8 10.8 months in group 2. In group 1, 16 patients were
HB5Ag positive, 8 were anti-HCV positive and 1 patient was positive for
both HB5Ag and anti-HCV. Of the HBsAg positive patients, 7 had chronic
persistent hepatitis (CPH), 8 were carriers, and 1 had hemosiderosis. All
the 8 anti-HCV positive patients and 1 HBsAg and anti-HCV positive
patient had CPH. Hepatic dysfunction developed significantly more in
group 1(12 patients, 48%) than in group 2 (1 patient, 4%) (P < 0.001). In
group 1 patients, the frequency of developing hepatic dysfunction post-
operatively was not different between patients with CPH and carrier state
(P> 0.05). The last follow-up creatinine level did not differ significantly
between the two groups (1.66 0.93 vs. 1.34 0.50 mg/dl, P > 0.05).
There were no significant differences in renal allograft rejection, infection,
graft and patients' survival rates between the two groups (P > 0.05). In
conclusion, renal transplantation in HBsAg and/or anti-HCV positive
patients with mild liver pathology was not associated with increased
incidence of rejection, decreased graft and patients' survival except for a
higher rate of hepatic dysfunction. However, a large number of patients
with long-term follow-up duration will be necessary to determine the more
precise clinical outcome of patients with positive viral markers.
Changes in T lymphocyte subset of peripheral blood induced by
preoperative immunosuppressive drug administration influence the de-
velopment of acute rejection of renal allograft. D. Chae, KH Kim, R. W.
Chun, Y C. Lee, J. W. Noh, and HR. Cho, Department of Internal Medicine,
and Department of General Surgery, Hallym University, Chuncheon, Korea.
We have already demonstrated that the frequency of development of
acute rejection of renal allografts increased in patients whose serum
soluble interleukin-2 receptor had not decreased after the administration
of preoperative immunosuppressive drugs. In the light of the above
findings we measured T lymphocyte subsets of peripheral blood by flow
cytometry before and after pre-operative administration of prednisolone
(PDL) and cyclosporin (C5A) for 2 days in 20 patients whose kidney
transplantations were done from April 1993 to January 1994 using kidneys
from living donors. The results obtained are as follows: (1) Acute rejection
developed in 7 patients (R group) but did not develop in 13 patients (NR
group) during the follow-up period of 3—12 months. There was no
difference in the degree of HLA A, B, or DR loci (2.0 1.0 loci in the R
group and 2.6 0.5 in the NR group). (2) After the administration of PDL
and CsA, the CD4/CD8 ratio in the NR group decreased from 1.55 0.65
to 0.97 0.61 (P = 0.00024), which resulted from a decrease in CD4. On
the contrary, the CD4/CD8 ratio in the R group showed no significant
change. (3) The index calculated from [CD4/CD8]pre/[CD4/CD8]post x
100 was lower in the R group than the NR group, showing less of a
decrease in the CD4/CD8 ratio in the R group (109.4 26.6 in the R
group, 176.4 55.7 in the NR group, P = 0.0017).
The clinical course of allograft IgA nephropathy. SB. Park, I. J00, H. C.
Kim, W.H. Cho, C.H. Park, and KK Par/c, Department of Internal Medicine,
Surgery, Urology and Pathology. Keimyung University School of Medicine,
Taegu, Korea. We have studied 21 patients with allograft IgA nephropathy
who have received a renal allografts from living-related donors. Thirteen
of these patients had HLA-one-haplotype matched kidneys, while 8 of the
patients received mismatched kidneys. There were 16 males and 5 females,
with a mean age of 32.9 2.5 years. The mean time at onset of clinical
signs after transplantation was 15.0 2.8 months. Proteinuria (55%) was
the most common initial manifestation of the allograft IgA nephropathy.
Other manifestations were microscopic hematuria (15%), proteinuria with
microscopic hematuria (10%), and gross hematuria (5%). All specimens
were found to exhibit intense mesangial localization of IgA by immuno-
fluorescence, with the presence of multiple immune complex-type deposits
in these areas confirmed ultrastructurally. Electron dense deposits were
present in the mesangial area in all specimens, subendothelial deposits in
6, intramembranous deposits in 4, and subepithelial deposits in one. By
light microscopy, there was slight to prominent mesangial thickening.
Focal and segmental glomerular changes were found in 8 patients.
Crescentic glomerulonephritis was associated with mesangial IgA deposits
in 2 patients. The clinical features of allograft IgA nephropathy were
variable. Twenty patients developed proteinuria with/without microscopic
hematuria. Ten patients had a nephrotic range proteinuria. The mean
duration of follow-up after renal transplantation was 49.6 5.9 months.
Sixteen patients experienced declining function of the allograft kidney
during their follow-up period. Eight patients had a functioning allograft
with renal insufficiency (Se. 1.8—5.0 mgldl) and 2 patients with deteriora-
tion of graft function (Sr >5.0 mg/dl). Six patients progressed to
end-stage renal disease and entered maintenance hemodialysis or CAPD
programs. We suggest that there was no difference between HLA-one-
haplotype and mismatched type patients in clinical features, severity, and
allograft kidney function. Allograft IgA nephropathy in living-related
donor renal transplantation is an important cause of graft failure with or
without rejection.
The roles of IL-i and TGF-j3 in chronic renal allograft rejection. D.C.
Han, S.Y. Jin, MS. Par/c, S.K Lee, S.D. Hwang, D.H. Lee, C. Moon, and
H.B. Lee, Hyonam Kidney Laboratory and Departments of Pathology and
General Surgery, Soon Chun Hyang University, Seoul, Korea. Chronic
rejection is a consequence of a long standing immunologic process and is
characterized by progressive glomerular and interstitial fibrosis and fi-
brous intimal thickening of arteries. Recently, several cytokines have been
shown to be responsible for chronic fibrosis and scarring in renal injury. To
investigate the roles of IL-i and TGF-f3 in human chronic allograft
rejection, we examined IL-i and TGF-13 gene expressions in the renal
allografts by hybridization using digoxigenin-labeled IL-lp eDNA probe
and digoxigenin-labeled TGF-3 PCR probe. (1) MCNS kidneys used as
control had no expression of IL-113 or TGF-/3 mRNA. (2) IL-1/3 gene
expressions were noted in the glomeruli in 2 of 4 graft kidney samples with
chronic rejection. (3) TGF-13 mRNA was prominently expressed in the
glomeruli and tubulointerstitium in all 4 graft samples with chronic
rejection. Conclusion: IL-113 and TGF-3 may have important roles in
mediating progressive renal injury in chronic renal allograft rejection.
Effect of enalapril on erythrocytosis in renal transplant recipients. YS.
Kim, S.H. Lee, C. W Yang, E.J. Choi, YS. Chang, YS. Yoon, and B.K Bang,
Dept. of Internal Medicine, Catholic University Medical College, Seoul,
Korea. Erythrocytosis in renal transplant recipients is associated with many
potential complications, such as hypertension, heart failure and thrombo-
embolic disease, and increased production of erythropoietin has been
focused on as a mechanism of erythrocytosis. Based on the report that
ACE inhibitors reduce circulating erythropoietin, we investigated the
effect of enalapril on the ejythrocytosis and the associated changes in
serum erythropoietin for 3 months in 15 renal transplant recipients whose
hematocrits were more than 50%. All patients were male, mean age was
40 (27—58) years, serum creatinine levels were below 2.0 mg/dl and mean
post-transplant duration was 25 (6—57) months. Patients were placed on
enalapril 10—20 mg/day according to their blood pressure. Fourteen
patients were receiving cyclosporine and prednisolone and 1 was receiving
triple therapy. One patient dropped out in the first month due to severe
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cough. Of the 14 patients, 10 were smokers, and 4 were non-smokers.
After 12 weeks of treatment, hematocrits fell from 51.4 1.6% to 40.8
5.0% (P < 0.0001). Of the 14 patients, 12 (86%) were responsive to
enalapril. Serum erythropoietin level also fell after 12 weeks. No signifi-
cant side effect was noted except a severe cough in 1 patient and a mild
increase in serum creatinine in 2 patients. In conclusion, enalapril is an
effective and safe treatment for post-renal transplant erythrocytosis, and
the reduction of circulating erythropoietin may be the possible mechanism
of the effect.
Five cases of rhabdomyolysis in kidney transplantation recipients due
to oral lipid lowering agents. L.S. Ahn, D.C. Jin, S.A. Yoon, S.J. Ahn, J.Y
Woo, WS. Koo, E.J. Choi, YS. Yoon, and B.K Bang, Department of Internal
Medicine, Catholic University Medical College, Seoul, Korea. As hyperlipid-
emia occurs frequently in renal transplant recipients (61%), oral lipid
lowering agents (HMG-C0A reductase inhibitor, fibric acid derivatives)
are commonly applied. In using oral lipid lowering agents with cyclosporin
A, a high incidence of rhabdomyolysis was reported. We recently experi-
enced five cases of rhabdomyolysis in kidney transplants. The patients
were admitted with the symptoms of muscle weakness, myalgia and they
were diagnosed with myoglobinuria and elevation of serum muscle
enzymes (CK, LDH, AST) by muscle biopsy.
course is favorable. We experienced 13 cases of AIHA [1.8%, M:F = 9.4;
age, 39 years (28—61)] among 729 renal transplant recipients and reviewed
the laboratory findings, treatments, and clinical courses of AIHA. The
results were as follows: (1) The incidence of AH-[A according to ABO-
minor-incompatibility was 8.0% (13/163). (2) The blood group of all
donors was 0 type and that of recipients was A type (10/64; 15.6%), B type
(2/47; 4.3%) and AB (1/15, 6.7%). (3) AIHA occurred 13.3 4.6 days(range 8—25) after renal transplantation and continued for 12.8 6.8days
(range 3—26). (4) The laboratory findings showed variable severity of
AIHA [hematocrit 20.9 5.5 (9—29)], [haptoglobin 80.2 93.4 mg/dl
(2—289)], [total bilirubin 3.9 2.9 mg/dl (0.5—10.9)], [LDH 8692 20755
lU/liter (544—70410)], [reticulocyte count 7.9 5.0% (0.7—10.9)]. (5)
Treatment was individualized according to the severity of All-IA: no
treatment (3 cases), azathioprine alone (5 cases), combination therapy of
azathioprine and plasmapheresis (6 cases). (5) The clinical course of
AIHA was favorable in 12 cases. However, 1 case expired due to fulminant
hemolytic crisis 3 days after onset of hemolysis. In conclusion: (1)
Nephrologists must be alert to unexpected reductions in hematocrit or
other signs of hemolysis in the early post-transplant period, especially in
ABO-minor-incompatible recipients. (2) Treatment must be individual-
ized according to the severity of AIHA. (3) In severe cases, careful
follow-up of laboratory findings and early treatment of AIHA may be
necessary to prevent a fatal hemolytic crisis.
Age/sex 47/F 41/F 52/M 41/M 36/F Acute pyelonephritis of graft kidney and renal failure in renal trans-
Post-KT 16 55 23 32 57 plant recipients. C.W. Yang, YS. Kim, E.J. Choi, IS. Park, WS. Koo, E.J.
duration Choi, YS. Chang, YS. Yoon, and B.K Bang, Department of Internal
month Medicine, Catholic University Medical College, Seou4 Korea. Acute pyelo-
Cholesterol/ 292/445 35 1/280 330/260 212/892 253/366 nephritis of grafted kidneys is often accompanied by renal failure in renal
triglyceride transplant recipients. Therefore, we performed this study to evaluate the
Enzyme prevalence of acute pyelonephritis of graft kidneys accompanied renal
peak-level failure, degree of impairment of renal function and management of acute
AST lU/liter 780 268 327 2,000 236 pyelonephritis in 705 renal transplants performed at Kangnam St. Mary's
CK lU/liter 15,140 9,430 3,510 13,344 5,008 Hospital. Acute pyelonephritis was confirmed by characteristic clinical
Serum over 300 196 over 300 over 300 over 300 manifestation (graft swelling, fever), routine urinalysis and positive urine
myoglobin, culture. Renal failure was defined by an increase in serum creatinine of 0.5
ng/ml mgldl compared to baseline, and renal biopsy was performed in patients
Serum 1.2 1.4 1.9 1.8 1.9 who showed persistent elevation of serum creatinine, in spite of improve-
creatinine, ment of clinical symptoms and in patients who needed differential
mg/dl diagnosis between acute rejection and acute pyelonephritis. The results
Lovastatin, 20 X 39 20 X 20 20 >< 11 no 20 x 25 were as follows: (1) The prevalence of acute pyelonephritis of graft kidney
mg/day x was 2.0% (14/705). Among them, 12 cases (85.3%) were accompanied by
Gemfibrozil, no no no 1,200 x 11 800>< 4 renal failure. (2) Impairment of renal function was mild to moderate, but
mg/day x wks 1 case needed hemodialysis. (3) The common etiologic organism was E.
coli (92.3%) and I case demonstrated Staphylococcus aureus on urine
culture. (4) Renal biopsy was performed in six cases. Among them, threeAll cases were recovered with conservative treatment without sequeale cases showed mild acute rejection (Banif classification, acute rejection
including well graft function. grade 1). These patients were treated with combination therapy of
antibiotics and steroids (methylprednisolone pulse therapy or increase in
Autoimmune hemolytic anemia following ABO-minor-incompatible re- prednisolone dose) with good clinical results. In conclusion, graft kidneys
nal transplantation in the cyclosporine era. HK Chun, S.H. Lee, C. W. with acute pyelonephritis are susceptible to renal failure, and this may be,
Yang, YS. Kim, W.S. Koo, E.J. Choi, YS. Yoon, and B.K Bang, Department in part, associated with acute graft rejection. Therefore, renal biopsy is
of Internal Medicine, Catholic University Medical College, Seoul Korea. It recommended to confirm the infection-triggered acute rejection and
has been reported that autoimmune hemolytic anemia (All-IA) often additional immunosuppressants should be included in the treatment of
develops in cyclosporine-treated renal transplant recipients and its clinical infection-triggered acute rejection.
